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Supplementary Table 1. Description of studies contributing to trans-ancestry meta-analysis: ancestry group and country of origin, sample 
size, data collection methods, and birth weight summaries and exclusions. 
 










Data collection Phenotype 
exclusions 
Mean (SD) birth weight (grams) Median (IQR) 
GA (week) at 
delivery 
Males Females Combined 
1958 British 
Birth Cohort 
European UK 1958 4,595 
(2,320/2,275) 
Measured by midwives; supplemented 
with obstetric records and interviews 
with mothers 









ALSPACa,b European UK ~1992 7,285 
(3,722/3,563) 
Identified from obstetric data, records 
from the ALSPAC measurers, and birth 
notification 
Multiple births,  GA 









CHOP-Caucasian European USA 1988-present 9,405 
(5,040/4,365) 
Questionnaire and medical records Multiple births, GA 









CoLaus European Switzerland 1928-1970 2,089 
(892/1,197) 







COPSAC-2000 European Denmark 1998-2001 352 
(173/179) 
Medical records Multiple births, GA 
<37 weeks 
N/A N/A 3555 
(485) 
40 (39-41) 
COPSAC-2010 European Denmark 2008-2011 589 
(306/283) 











European Denmark 1987-1999 1,210 
(804/406) 









DNBC European Denmark 1996-2003 915 
(475/440) 











ERF European Netherlands Various 459 
(187/272) 







EPIC European UK 1993-1997 8,939 
(3,448/5,491) 







Fenland (GA+) European UK 1950-1975 5,188 
(2,088/3,100) 
Self-reported as adults  GA described as 









Fenland (GA-) European UK 1950-1975 833 
(509/324) 







Generation R European Netherlands 2002-2006 2,701 
(1,378/1,323) 
Hospital records and community 
midwives 











European Germany 1996-1999 656 
(360/296) 
Parental report of medical records  Multiple births, GA 

















Data collection Phenotype 
exclusions 
Mean (SD) birth weight (grams) Median (IQR) 
GA (week) at 
delivery 
Males Females Combined 
GINIplus & 
LISAplus (GA-) 
European Germany 1996-1999 790 
(391/399) 
Parental report of medical records  Multiple births, GA 








GOYA European Denmark 1943-1952 149/0 (obese), 
141/0 (control) 
School health records N/A N/A N/A 3553 
(711) 
N/A 
HBCS European Finland 1934-1944 1472 
(639/833) 









INMA European Spain 1997-2006 1,021 
(527/494) 







INTER99 European Denmark 1939-1969 4,243 
(1,981/2,262) 
Measured by midwives and obtained 
from obstetric record registry 









Leipzig European Germany 1985 - 2010 597 (304/293) Questionnaire to mothers, 
documentation of medical screening 
examination if available 



















NFBC1966 European Finland 1966 5,009 
(2,393/2,616) 
Measured in hospitals Multiple births, GA 









NFBC1986 European Finland 1986 4,680 
(2,306/2,374) 
Measured in hospitals Multiple births, GA 









NTR European Netherlands 1926-1998 1,265 
(447/818) 









ORCADES European Scotland 1920-1991 960 
(330/630) 







PANIC European Finland 1999-2002 436 
(231/205) 
Medical records and parental 
questionnaire  









RAINE European Australia 1989-1991 1,347 
(693/654) 
Recorded at delivery by study personnel 
or obtained from hospital reports  









SORBS European Germany 1925-1988 298 
(113/185) 
Interview at recruitment N/A N/A N/A 3393 
(673) 
N/A 
STRIP European Finland 1989-1991 599 
(311/288) 









TEENAGE (GA+) European Greece 1993-1998 279 
(126/153)  
Measured by midwives or paediatricians; 
supplemented with data from mothers’ 
interviews 







TEENAGE (GA-) European Greece 1993-1998 551 
(234/317) 
Measured by midwives or paediatricians; 









TDCOB-cases European Denmark 1987-2007 669 Measured by midwives and registered in Multiple births 3682 3629 3660 40 (39-41) 
 5 
(391/278) Danish Civil Registry (536) (545) (540) 
TDCOB-controls European Denmark 1991-2006 560 
(211/349) 
Measured by midwives and registered in 
Danish Civil Registry 







YFS European Finland 1962-1977 1,915 
(861/1,054) 
Mothers’ interview Multiple births, GA 



















Data collection Phenotype exclusions Mean (SD) birth weight (grams) Median (IQR) 




UK BioBank European UK 2006-2010 67,786 
(40,425/27,361) 
Self-reported as adults Multiple births, birth 



















Data collection Phenotype exclusions Mean (SD) birth weight (grams) Median (IQR) 
GA (weeks) at 
delivery 
Males Females Combined 
CHOP-AA African 
American 
USA 1988-present 6,635 
(3,343/3,292) 
Questionnaire and medical records Multiple births, GA 









CLHNS Filipino Philippines 1983-84 1,449 
(755/694) 











Turkish Netherlands 2002-2006 420 
(215/205) 
Hospital records and community 
midwives 











Moroccan Netherlands 2002-2006 365 
(188/177) 
Hospital records and community 
midwives 











Surinamese Netherlands 2002-2006 395 
(215/180) 
Hospital records and community 
midwives 









SCORM Chinese Singapore 1992-1995 840 
(420/420) 








M, Males; F, Females; GA, gestational age; IQR, interquartile range; N/A, not applicable; SD, standard deviation. 
aBoyd A, Golding J, Macleod J, Lawlor DA, Fraser A, et al. Cohort Profile: the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and 
Children. Int J Epidemiol 42, 111-127 (2013).  




Supplementary Table 2. Description of studies contributing to trans-ancestry meta-analysis: genotyping, quality control, pre-phasing, 
imputation, and association analysis. 
(a) Component 1: European ancestry GWAS 
Study Genotyping 
array(s)a 
Sample quality control SNP scaffold quality control Prephasing 
software 
Imputation Association analysis Lambda 
(M/F) Call rate Additional filters Call rate HWE 
P-value 
Frequency Software Reference 
panel 




I550, I610 None Relatedness, ancestry outliers, 
sex discrepancy, identity, 
channel contrast  
95% 1x10-4 MAF<1% MaCH Minimac 1000G   
Mar 2012 
ProbABEL GA 1.01/1.00 
ALSPAC I550 97% Heterozygosity, relatedness, 
ancestry outliers 
95% 5×10-7 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC7 1.02/1.01 
CHOP-
Caucasian 
I550, I610 95% Relatedness, ancestry outliers, 
sex discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-3 0.96/0.96 
CoLaus A5 90% Relatedness, ancestry outliers 90% 1x10-7 MAF<1% MaCH Minimac 1000G   
Mar 2012 
In-house None 0.99/1.00 
COPSAC-2000 I550  97.5% Heterozygosity, relatedness, 
ancestry outliers 
98% 1x10-6 MAF<0.1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA 1.00/1.01 
COPSAC-2010 IOEE 95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
QuickTest GA, PC1-5 1.01/1.00 
COPSAC-
REGISTRY 
IOEE 95% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
97.5% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
QuickTest GA, PC1-5 1.00/1.00 
DNBC I660 96% Heterozygosity, ancestry 
outliers, sex discrepancy 
98% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 1.00/1.00 
ERF Various 98% Relatedness, ancestry outliers, 
sex discrepancy 





EPIC AUKBB 97% Heterozygosity, relatedness, 
sex discrepancy, singletons, 
channel contrast 
95% 1x10-6 MAC<1 SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-10 1.00/1.01 
Fenland (GA+) AUKBB 95% Sex discrepancy, identity 95% 1x10-6 MAC<2 SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-10 1.00/1.01 
Fenland (GA-) AUKBB 95% Sex discrepancy, identity 95% 1x10-6 MAC<2 SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-10 0.99/1.00 
Generation R I610, I660 97.5% Heterozygosity, ancestry 
outliers, sex discrepancy 
98% 1x10-6 MAF<1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA, PC1-4 1.03/1.01 
GINIplus & 
LISAplus 
A5, A6 95% Heterozygosity, ancestry 
outliers, sex discrepancy 
95% 1x10-5 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 0.99/1.00 
GOYA I610 95% Heterozygosity, ancestry 
outliers, sex discrepancy 
95% 1x10-7 MAF<1% MaCH MaCH 1000G   
Mar 2012 
QuickTest None 1.00/0.99 
 
HBCS I670 95% Heterozygosity, relatedness, 
ancestry outliers 
95% 1x10-6 MAF<1% MaCH MaCH 1000G   
Mar 2012 




Sample quality control SNP scaffold quality control Prephasing 
software 
Imputation Association analysis Lambda 
(M/F) Call rate Additional filters Call rate HWE     
p-value 
Frequency Software Reference 
panel 
Software Covariates or 
adjustment 
INMA IOQ 98% Heterozygosity, relatedness, 
ancestry outliers, duplicates 
95% 1.1x10-6 MAF<1% IMPUTE2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 1.00/0.99 
INTER99 ICM 95% Relatedness, ancestry outliers, 
sex discrepancy 
95% 1x10-4 MAF<1% IMPUTE2 IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1 0.97/1.02 





1x10-4 MAF<1% IMPUTE2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 0.95/0.96 
NEO ICE 98% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
98% 1x10-6 None IMPUTE2 IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-5 0.99/0.99 
NFBC1966 I370 95% Heterozygosity, relatedness, 






5.7x10-7 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-3 1.00/0.99 
NFBC1986 ICM 95% Heterozygosity, relatedness, 









MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-3 1.00/1.10 
NTR A6, I370, I660, 
IOQ 
90% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
95% 1x10-5 MAF<1% MaCH Minimac 1000G   
Mar 2012 





ORCADES I300, IOQ, IOE 95% Heterozygosity, relatedness, 





1x10-6 MAF<1% SHAPEIT IMPUTE2 1000G Mar 
2012 
ProbABEL array, PC1-3 1.00/0.99 
PANIC ICM, ICE 90 % Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-4 1.01/1.01 
RAINE I660 97% Heterozygosity, relatedness, 
ancestry outliers, sex 
discrepancy, chromosomal 
abnormalities 
95% 5.7x10-7 MAF<1% MaCH MaCH 1000G   
Mar 2012 
ProbABEL GA, PC1-2 1.01/0.99 
SORBS I660 94% Relatedness, ancestry outliers, 
sex discrepancy, duplicates 





STRIP A5, A6 95% Heterozygosity, ancestry 
outliers, twins 
95% 1x10-6 MAF<0.1% SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1-4 1.01/1.01 
TEENAGE (GA+) ICM 95% Heterozygosity, relatedness, 





1x10-4 MAF<1% SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 1.02/1.00 
TEENAGE (GA-) IOE  95% Heterozygosity, relatedness, 





1x10-4 MAF<1% SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST None 1.02/0.98 
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TDCOB-cases IOE 95% Heterozygosity, relatedness, 
ancestry outliers 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1 1.02/1.01 
TDCOB-
controls 
ICE 95% Heterozygosity, relatedness, 
ancestry outliers 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA, PC1 1.02/1.05 
YFS I670 95% Heterozygosity, relatedness, 
sex discrepancy, duplicates 
95% 1x10-6 MAF<1% SHAPEIT IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-4 0.99/1.01 
 




Sample quality control SNP scaffold quality control Prephasing 
software 
Imputation Association analysis Lambda 
Call rate Additional filters Call rate HWE 
P-value 
Frequency Software Reference 
panel 
Software Covariates or 
adjustment 
UK BioBank AUKBB 98% Heterozygosity, relatedness, 
ancestry outliers 
95% N/A MAF<1% SHAPEIT2 IMPUTE2 1000G    
Oct 2014 & 
UK10K 








Sample quality control SNP scaffold quality control Prephasing 
software 
Imputation Association analysis Lambda 
(M/F) Call rate Additional filters Call rate HWE 
P-value 
Frequency Software Reference 
panel 
Software Covariates or 
adjustment 
CHOP-AA I550, I610 95% Relatedness, ancestry outliers, 
sex discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST PC1-3 0.98/0.98 
CLHNS ICM 98.6% Relatedness, sex discrepancy 97% 1×10-6 N/A MaCH MaCH 1000G   
Mar 2012 
mach2qtl GA 1.02/1.02 
Generation R 
Turkish 
I610, I660 97.5% Heterozygosity, ancestry 
outliers, sex discrepancy 
95% 1x10-7 MAF<1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA, PC1-4 1.01/1.02 
Generation R 
Moroccan 
I610, I660 97.5% Heterozygosity, ancestry 
outliers, sex discrepancy 
90% 1x10-7 MAF<1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA, PC1-4 1.01/0.98 
Generation R 
Surinamese 
I610, I660 97.5% Heterozygosity, ancestry 
outliers, sex discrepancy 
98% 1x10-7 MAF<1% MaCH Minimac 1000G   
Mar 2012 
mach2qtl GA, PC1 0.99/0.95 
SCORM I550 95% Heterozygosity, relatedness, 
sex discrepancy 
95% 1x10-6 MAF<1% SHAPEIT2 IMPUTE2 1000G   
Mar 2012 
SNPTEST GA 0.98/0.99 
 
HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; MAC, minor allele count; GA, gestational age; PC, principal component. 
aGenotype array codes: Affymetrix 5.0 (A5); Affymetrix 6.0 (A6); Affymetrix Axiom UK BiLEVE (AUKBL); Affymetrix Axiom UK BioBank (AUKBB); Illumina Human370CNV 
(I370); Illumina HumanHap550 (I550); Illumina HumanHap610 (I610); Illumina HumanHap660 (I660); Illumina HumanHap670 (I670); Illumina CardioMetabochip (ICM); 
Illumina OmniQuad (IOQ); Illumina OmniExpress (IOE); Illumina CoreExome (ICE); Illumina OmniExpressExome (IOEE).   
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Supplementary Table 3. BW association summary statistics for each component of the 
trans-ancestry meta-analysis of 153,781 individuals for lead SNPs at loci attaining genome-
wide significance (P<5x10-8).  
 
Locus: WNT4-ZBTB40.  Lead SNP: rs2473248.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.86 0.039 0.008 5.0x10-7 71,642 0.66 
Component 2: UKBB 0.88 0.025 0.008 0.0032 67,786 N/A 
European ancestry meta-analysis 0.87 0.033 0.006 1.1x10-8 139,428 0.21 
Component 3: non-European ancestry 0.78 0.039 0.018 0.034 8,653 0.43 
Trans-ancestry meta-analysis 0.87 0.033 0.005 1.1x10-9 148,081 0.72 
 
Locus: ZBTB7B.  Lead SNP: rs3753639.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.23 0.038 0.006 3.9x10-9 70,376 0.60 
Component 2: UKBB 0.25 0.024 0.006 0.00017 67,786 N/A 
European ancestry meta-analysis 0.24 0.031 0.004 7.3x10-12 138,162 0.12 
Component 3: non-European ancestry 0.18 0.037 0.020 0.061 8,655 0.40 
Trans-ancestry meta-analysis 0.23 0.031 0.004 1.3x10-12 146,817 0.72 
 
Locus: FCGR2B.  Lead SNP: rs72480273.  Effect/other alleles: C/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.16 0.029 0.007 8.7x10-5 70,594 0.14 
Component 2: UKBB 0.19 0.033 0.007 2.3x10-6 67,786 N/A 
European ancestry meta-analysis 0.17 0.031 0.005 8.0x10-10 138,380 0.69 
Component 3: non-European ancestry 0.15 0.005 0.023 0.84 8,655 0.71 
Trans-ancestry meta-analysis 0.17 0.030 0.005 1.5x10-9 147,035 0.86 
 
Locus: DTL.  Lead SNP: rs61830764.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.38 0.031 0.006 1.0x10-7 70,372 0.12 
Component 2: UKBB 0.38 0.013 0.006 0.019 67,786 N/A 
European ancestry meta-analysis 0.38 0.022 0.004 5.6x10-8 138,158 0.029 
Component 3: non-European ancestry 0.15 0.016 0.024 0.50 8,655 0.30 
Trans-ancestry meta-analysis 0.36 0.022 0.004 4.5x10-8 146,813 0.18 
 
Locus: ATAD2B.  Lead SNP: rs7575873.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.88 0.040 0.008 4.9x10-7 71,639 0.98 
Component 2: UKBB 0.87 0.036 0.008 6.3x10-6 67,786 N/A 
European ancestry meta-analysis 0.88 0.038 0.006 1.3x10-11 139,425 0.71 
Component 3: non-European ancestry 0.93 -0.011 0.027 0.67 10,104 0.61 
Trans-ancestry meta-analysis 0.88 0.036 0.006 6.2x10-11 149,529 0.35 
 
Locus: EPAS1.  Lead SNP: rs1374204.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.70 0.050 0.006 1.0x10-16 66,667 0.94 
Component 2: UKBB 0.70 0.044 0.006 9.7x10-14 67,786 N/A 
European ancestry meta-analysis 0.70 0.047 0.004 6.2x10-29 134,453 0.42 
Component 3: non-European ancestry 0.63 0.031 0.016 0.049 8,654 0.14 




Locus: PTH1R.  Lead SNP: rs2242116.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.38 0.018 0.005 0.00048 75,884 0.48 
Component 2: UKBB 0.38 0.025 0.006 5.5x10-6 67,786 N/A 
European ancestry meta-analysis 0.38 0.022 0.004 1.4x10-8 143,670 0.37 
Component 3: non-European ancestry 0.57 0.012 0.014 0.41 10,103 0.92 
Trans-ancestry meta-analysis 0.39 0.021 0.004 1.2x10-8 153,773 0.94 
 
Locus: ADCY5.  Lead SNP: rs11719201.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.22 0.052 0.006 5.2x10-18 75,884 0.34 
Component 2: UKBB 0.24 0.039 0.006 4.0x10-10 67,786 N/A 
European ancestry meta-analysis 0.23 0.046 0.004 2.4x10-26 143,670 0.14 
Component 3: non-European ancestry 0.13 0.037 0.022 0.095 9,264 0.18 
Trans-ancestry meta-analysis 0.23 0.046 0.004 6.4x10-27 152,934 0.35 
 
Locus: CPA3.  Lead SNP: rs10935733.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.42 0.023 0.005 2.2x10-5 71,640 0.58 
Component 2: UKBB 0.39 0.021 0.005 0.00012 67,786 N/A 
European ancestry meta-analysis 0.41 0.022 0.004 9.2x10-9 139,426 0.80 
Component 3: non-European ancestry 0.60 0.038 0.015 0.013 10,103 0.62 
Trans-ancestry meta-analysis 0.42 0.023 0.004 6.2x10-10 149,529 0.33 
 
Locus: CCNL1-LEKR1.  Lead SNP: rs13322435.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.60 0.063 0.005 1.0x10-30 71,640 0.0091 
Component 2: UKBB 0.60 0.042 0.006 3.4x10-13 67,786 N/A 
European ancestry meta-analysis 0.60 0.053 0.004 3.7x10-41 139,426 0.0080 
Component 3: non-European ancestry 0.45 0.040 0.015 0.0066 10,103 0.66 
Trans-ancestry meta-analysis 0.59 0.052 0.004 1.3x10-42 149,529 0.14 
 
Locus: LCORL.  Lead SNP: rs925098.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.28 0.040 0.006 4.8x10-12 71,640 0.46 
Component 2: UKBB 0.26 0.027 0.006 9.0x10-6 67,786 N/A 
European ancestry meta-analysis 0.27 0.034 0.004 5.4x10-16 139,426 0.11 
Component 3: non-European ancestry 0.34 0.011 0.015 0.44 10,102 0.28 
Trans-ancestry meta-analysis 0.28 0.032 0.004 1.3x10-15 149,528 0.060 
 
Locus: HHIP.  Lead SNP: rs6537307.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.023 0.005 1.5x10-5 71,645 0.35 
Component 2: UKBB 0.49 0.029 0.005 1.1x10-7 67,786 N/A 
European ancestry meta-analysis 0.50 0.025 0.004 9.5x10-12 139,431 0.41 
Component 3: non-European ancestry 0.21 0.038 0.018 0.036 9,557 0.92 
Trans-ancestry meta-analysis 0.48 0.026 0.004 1.3x10-12 148,988 0.80 
 
Locus: 5q11.2.  Lead SNP: rs854037.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.81 0.038 0.007 7.8x10-9 71,643 0.021 
Component 2: UKBB 0.82 0.014 0.007 0.045 67,786 N/A 
European ancestry meta-analysis 0.81 0.027 0.005 2.2x10-8 139,429 0.011 
Component 3: non-European ancestry 0.53 0.009 0.014 0.52 10,103 0.29 
Trans-ancestry meta-analysis 0.80 0.025 0.005 3.5x10-8 149,532 0.010 
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Locus: EBF1.  Lead SNP: rs7729301.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.72 0.021 0.006 0.00035 75,883 0.23 
Component 2: UKBB 0.74 0.027 0.006 1.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.73 0.024 0.004 1.6x10-8 143,669 0.48 
Component 3: non-European ancestry 0.58 0.033 0.014 0.022 10,104 0.64 
Trans-ancestry meta-analysis 0.72 0.025 0.004 1.3x10-9 153,773 0.78 
 
Locus: CDKAL1.  Lead SNP: rs35261542.  Effect/other alleles: C/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.72 0.047 0.006 6.1x10-17 75,881 0.94 
Component 2: UKBB 0.74 0.041 0.006 1.4x10-11 67,786 N/A 
European ancestry meta-analysis 0.73 0.044 0.004 4.4x10-27 143,667 0.49 
Component 3: non-European ancestry 0.75 0.044 0.016 0.0059 10,102 0.35 
Trans-ancestry meta-analysis 0.73 0.044 0.004 9.7x10-29 153,769 0.42 
 
Locus: HIST1H2BE.  Lead SNP: rs9379832.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.67 0.029 0.006 7.2x10-7 70,375 1.0 
Component 2: UKBB 0.73 0.016 0.006 0.011 67,786 N/A 
European ancestry meta-analysis 0.70 0.023 0.004 6.6x10-8 138,161 0.13 
Component 3: non-European ancestry 0.77 0.044 0.021 0.038 10,103 0.70 
Trans-ancestry meta-analysis 0.71 0.024 0.004 1.2x10-8 148,264 0.42 
 
Locus: HMGA1.  Lead SNP: rs7742369.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.17 0.027 0.007 0.0011 69,259 0.90 
Component 2: UKBB 0.18 0.030 0.007 2.4x10-5 67,786 N/A 
European ancestry meta-analysis 0.18 0.028 0.005 1.0x10-8 137,045 0.77 
Component 3: non-European ancestry 0.44 0.013 0.016 0.41 9,561 0.18 
Trans-ancestry meta-analysis 0.19 0.027 0.005 1.1x10-8 146,606 0.16 
 
Locus: L3MBTL3.  Lead SNP: rs1415701.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.75 0.025 0.006 2.3x10-5 75,880 0.69 
Component 2: UKBB 0.73 0.025 0.006 3.2x10-5 67,786 N/A 
European ancestry meta-analysis 0.74 0.025 0.004 2.6x10-9 143,666 1.00 
Component 3: non-European ancestry 0.63 0.048 0.015 0.0013 10,102 0.64 
Trans-ancestry meta-analysis 0.73 0.027 0.004 4.0x10-11 153,768 0.40 
 
Locus: ESR1.  Lead SNP: rs1101081.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.72 0.044 0.006 5.4x10-14 71,641 0.95 
Component 2: UKBB 0.73 0.031 0.006 2.7x10-7 67,786 N/A 
European ancestry meta-analysis 0.72 0.038 0.004 1.6x10-19 139,427 0.14 
Component 3: non-European ancestry 0.79 0.027 0.017 0.13 10,103 0.47 
Trans-ancestry meta-analysis 0.73 0.037 0.004 6.1x10-20 149,530 0.28 
 
Locus: GNA12.  Lead SNP: rs798489.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.73 0.020 0.006 0.00040 75,884 0.75 
Component 2: UKBB 0.73 0.027 0.006 1.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.73 0.023 0.004 2.0x10-8 143,670 0.44 
Component 3: non-European ancestry 0.92 0.053 0.027 0.048 9,708 0.14 
Trans-ancestry meta-analysis 0.74 0.024 0.004 5.0x10-9 153,378 0.84 
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Locus: IGF2BP3.  Lead SNP: rs11765649.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.76 0.021 0.006 0.00049 71,642 0.80 
Component 2: UKBB 0.74 0.032 0.006 1.3x10-7 67,786 N/A 
European ancestry meta-analysis 0.75 0.027 0.004 5.8x10-10 139,428 0.19 
Component 3: non-European ancestry 0.87 0.003 0.022 0.88 10,103 0.37 
Trans-ancestry meta-analysis 0.76 0.026 0.004 1.0x10-9 149,531 0.60 
 
Locus: TBX20.  Lead SNP: rs6959887.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.61 0.031 0.005 1.4x10-9 75,873 0.58 
Component 2: UKBB 0.61 0.013 0.006 0.021 67,786 N/A 
European ancestry meta-analysis 0.61 0.023 0.004 1.5x10-9 143,659 0.013 
Component 3: non-European ancestry 0.63 -0.007 0.014 0.65 10,098 0.62 
Trans-ancestry meta-analysis 0.61 0.021 0.004 1.0x10-8 153,757 0.054 
 
Locus: YKT6-GCK.  Lead SNP: rs138715366.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.9908 0.227 0.034 1.7x10-11 64,557 0.86 
Component 2: UKBB 0.9915 0.253 0.031 7.1x10-16 67,786 N/A 
European ancestry meta-analysis 0.9911 0.241 0.023 7.2x10-26 132,343 0.57 
Component 3: non-European ancestry 0.9977 0.855 0.333 0.010 3,292 1.00 
Trans-ancestry meta-analysis 0.9913 0.244 0.023 1.4x10-26 135,635 0.16 
 
Locus: MLXIPL.  Lead SNP: rs62466330.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.06 0.052 0.011 1.9x10-6 74,414 0.24 
Component 2: UKBB 0.07 0.046 0.011 1.5x10-5 67,786 N/A 
European ancestry meta-analysis 0.07 0.049 0.008 1.2x10-10 142,200 0.70 
Component 3: non-European ancestry 0.04 0.142 0.045 0.0015 7,815 0.52 
Trans-ancestry meta-analysis 0.07 0.051 0.007 5.9x10-12 150,015 0.23 
 
Locus: ANK1-NKX6-3.  Lead SNP: rs13266210.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.78 0.023 0.006 0.00034 71,643 0.19 
Component 2: UKBB 0.79 0.040 0.007 1.5x10-9 67,786 N/A 
European ancestry meta-analysis 0.79 0.031 0.005 1.3x10-11 139,429 0.054 
Component 3: non-European ancestry 0.81 0.013 0.019 0.48 9,562 0.30 
Trans-ancestry meta-analysis 0.79 0.030 0.004 1.6x10-11 148,991 0.32 
 
Locus: TRIB1.  Lead SNP: rs6989280.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.73 0.026 0.006 5.6x10-6 75,885 0.34 
Component 2: UKBB 0.73 0.017 0.006 0.0069 67,786 N/A 
European ancestry meta-analysis 0.73 0.022 0.004 2.2x10-7 143,671 0.25 
Component 3: non-European ancestry 0.32 0.027 0.016 0.085 10,104 0.85 
Trans-ancestry meta-analysis 0.70 0.022 0.004 5.0x10-8 153,775 0.92 
 
Locus: SLC45A4.  Lead SNP: rs12543725.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.59 0.023 0.005 1.1x10-5 71,645 0.39 
Component 2: UKBB 0.59 0.023 0.005 3.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.59 0.023 0.004 1.2x10-9 139,431 0.94 
Component 3: non-European ancestry 0.78 0.005 0.018 0.78 8,653 0.42 
Trans-ancestry meta-analysis 0.60 0.022 0.004 1.9x10-9 148,084 0.65 
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Locus: PTCH1.  Lead SNP: rs28510415.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.09 0.041 0.009 1.4x10-5 66,960 0.40 
Component 2: UKBB 0.10 0.070 0.009 1.7x10-14 67,786 N/A 
European ancestry meta-analysis 0.09 0.056 0.007 1.5x10-17 134,746 0.023 
Component 3: non-European ancestry 0.03 -0.086 0.043 0.049 8,654 0.79 
Trans-ancestry meta-analysis 0.09 0.053 0.006 4.0x10-16 143,400 0.0055 
 
Locus: LPAR1.  Lead SNP: rs2150052.  Effect/other alleles: T/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.021 0.005 8.6x10-5 71,638 0.23 
Component 2: UKBB 0.51 0.021 0.005 7.5x10-5 67,786 N/A 
European ancestry meta-analysis 0.50 0.021 0.004 2.2x10-8 139,424 0.95 
Component 3: non-European ancestry 0.46 0.008 0.015 0.61 8,655 0.71 
Trans-ancestry meta-analysis 0.50 0.020 0.004 2.8x10-8 148,079 0.99 
 
Locus: PHF19.  Lead SNP: rs7847628.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.68 0.028 0.006 1.1x10-6 71,638 0.47 
Component 2: UKBB 0.68 0.018 0.006 0.0014 67,786 N/A 
European ancestry meta-analysis 0.68 0.023 0.004 1.0x10-8 139,424 0.23 
Component 3: non-European ancestry 0.57 0.017 0.015 0.25 10,104 0.30 
Trans-ancestry meta-analysis 0.67 0.023 0.004 5.4x10-9 149,528 0.17 
 
Locus: STRBP.  Lead SNP: rs700059.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.15 0.027 0.007 0.00028 71,641 0.090 
Component 2: UKBB 0.14 0.040 0.008 2.1x10-7 67,786 N/A 
European ancestry meta-analysis 0.14 0.033 0.005 4.7x10-10 139,427 0.22 
Component 3: non-European ancestry 0.43 0.059 0.016 0.00018 8,653 0.34 
Trans-ancestry meta-analysis 0.16 0.036 0.005 1.2x10-12 148,080 0.21 
 
Locus: HHEX-IDE.  Lead SNP: rs61862780.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.51 0.027 0.005 9.2x10-8 75,884 0.37 
Component 2: UKBB 0.51 0.029 0.005 7.6x10-8 67,786 N/A 
European ancestry meta-analysis 0.51 0.028 0.004 3.0x10-14 143,670 0.81 
Component 3: non-European ancestry 0.77 0.025 0.017 0.13 10,103 0.12 
Trans-ancestry meta-analysis 0.52 0.028 0.004 9.5x10-15 153,773 0.80 
 
Locus: NT5C2.  Lead SNP: rs74233809.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.08 0.032 0.009 0.00039 75,881 0.88 
Component 2: UKBB 0.08 0.042 0.010 3.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.08 0.037 0.007 5.2x10-8 143,667 0.49 
Component 3: non-European ancestry 0.12 0.061 0.022 0.0057 10,104 0.39 
Trans-ancestry meta-analysis 0.08 0.039 0.006 1.8x10-9 153,771 0.14 
 
Locus: ADRB1.  Lead SNP: rs7076938.  Effect/other alleles: T/C. 
Analysis EAF Β SE P-value N Q P-value 
Component 1: European ancestry 0.73 0.046 0.006 1.3x10-15 75,885 0.79 
Component 2: UKBB 0.73 0.025 0.006 4.5x10-5 67,786 N/A 
European ancestry meta-analysis 0.73 0.036 0.004 4.7x10-18 143,671 0.011 
Component 3: non-European ancestry 0.64 0.018 0.015 0.22 10,103 0.56 
Trans-ancestry meta-analysis 0.73 0.035 0.004 4.7x10-18 153,774 0.19 
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Locus: PLEKHA1.  Lead SNP: rs2421016.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.022 0.005 1.0x10-5 75,873 0.25 
Component 2: UKBB 0.47 0.019 0.005 0.00047 67,786 N/A 
European ancestry meta-analysis 0.49 0.021 0.004 1.8x10-8 143,659 0.62 
Component 3: non-European ancestry 0.40 0.021 0.014 0.15 10,100 0.28 
Trans-ancestry meta-analysis 0.48 0.021 0.004 6.1x10-9 153,759 0.83 
 
Locus: INS-IGF2.  Lead SNP: rs72851023.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.07 0.055 0.011 6.7x10-7 67,990 0.014 
Component 2: UKBB 0.08 0.041 0.010 8.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.07 0.048 0.008 2.9x10-10 135,776 0.35 
Component 3: non-European ancestry 0.02 -0.048 0.064 0.45 7,815 1.00 
Trans-ancestry meta-analysis 0.07 0.046 0.007 6.8x10-10 143,591 0.64 
 
Locus: MTNR1B.  Lead SNP: rs10830963.  Effect/other alleles: G/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.28 0.029 0.006 5.1x10-7 75,877 0.20 
Component 2: UKBB 0.28 0.017 0.006 0.0059 67,786 N/A 
European ancestry meta-analysis 0.28 0.023 0.004 2.9x10-8 143,663 0.12 
Component 3: non-European ancestry 0.20 -0.013 0.021 0.54 10,102 0.76 
Trans-ancestry meta-analysis 0.27 0.022 0.004 1.0x10-7 153,765 0.23 
 
Locus: APOLD1.  Lead SNP: rs11055034.  Effect/other alleles: C/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.74 0.028 0.006 2.1x10-6 75,867 0.91 
Component 2: UKBB 0.72 0.016 0.006 0.0099 67,786 N/A 
European ancestry meta-analysis 0.73 0.022 0.004 1.8x10-7 143,653 0.13 
Component 3: non-European ancestry 0.81 0.046 0.020 0.019 9,942 0.67 
Trans-ancestry meta-analysis 0.73 0.023 0.004 2.3x10-8 153,595 0.32 
 
Locus: ABCC9.  Lead SNP: rs139975827.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.61 0.027 0.007 4.9x10-5 55,417 0.72 
Component 2: UKBB 0.63 0.023 0.006 5.8x10-5 67,786 N/A 
European ancestry meta-analysis 0.62 0.025 0.004 1.1x10-8 123,203 0.72 
Component 3: non-European ancestry 0.70 -0.018 0.018 0.32 8,655 0.68 
Trans-ancestry meta-analysis 0.63 0.022 0.004 1.0x10-7 131,858 0.22 
 
Locus: ITPR2.  Lead SNP: rs12823128.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.54 0.017 0.005 0.00086 71,645 0.59 
Component 2: UKBB 0.53 0.025 0.005 3.8x10-6 67,786 N/A 
European ancestry meta-analysis 0.54 0.021 0.004 1.9x10-8 139,431 0.32 
Component 3: non-European ancestry 0.86 0.000 0.021 1.0 10,103 0.054 
Trans-ancestry meta-analysis 0.56 0.020 0.004 3.2x10-8 149,534 0.65 
 
Locus: HMGA2.  Lead SNP: rs1351394.  Effect/other alleles: T/C. 
Analysis EAF Β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.048 0.005 7.6x10-21 75,885 0.40 
Component 2: UKBB 0.49 0.039 0.005 3.1x10-13 67,786 N/A 
European ancestry meta-analysis 0.49 0.044 0.004 1.9x10-32 143,671 0.24 
Component 3: non-European ancestry 0.34 0.033 0.015 0.028 10,102 0.75 
Trans-ancestry meta-analysis 0.48 0.043 0.004 2.0x10-33 153,773 0.72 
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Locus: IGF1.  Lead SNP: rs7964361.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.08 0.038 0.009 5.6x10-5 71,642 0.63 
Component 2: UKBB 0.09 0.040 0.010 2.3x10-5 67,786 N/A 
European ancestry meta-analysis 0.09 0.039 0.007 4.7x10-9 139,428 0.86 
Component 3: non-European ancestry 0.03 -0.010 0.040 0.81 9,264 0.21 
Trans-ancestry meta-analysis 0.08 0.038 0.007 9.7x10-9 148,692 0.20 
 
Locus: LINC00332.  Lead SNP: rs2324499.  Effect/other alleles: G/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.68 0.026 0.006 7.9x10-6 71,639 0.25 
Component 2: UKBB 0.67 0.018 0.006 0.0019 67,786 N/A 
European ancestry meta-analysis 0.68 0.022 0.004 7.3x10-8 139,425 0.34 
Component 3: non-European ancestry 0.60 0.034 0.016 0.027 8,655 0.41 
Trans-ancestry meta-analysis 0.67 0.023 0.004 8.3x10-9 148,080 0.64 
 
Locus: RB1.  Lead SNP: rs2854355.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.28 0.024 0.006 0.00012 69,775 0.036 
Component 2: UKBB 0.26 0.023 0.006 0.00024 67,786 N/A 
European ancestry meta-analysis 0.27 0.023 0.004 9.8x10-8 137,561 0.91 
Component 3: non-European ancestry 0.19 0.037 0.020 0.066 8,654 0.86 
Trans-ancestry meta-analysis 0.26 0.024 0.004 2.2x10-8 146,215 0.63 
 
Locus: RNF219-AS1.  Lead SNP: rs1819436.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.86 0.041 0.008 2.4x10-7 71,193 0.19 
Component 2: UKBB 0.88 0.024 0.008 0.0030 67,786 N/A 
European ancestry meta-analysis 0.87 0.033 0.006 6.3x10-9 138,979 0.14 
Component 3: non-European ancestry 0.84 0.033 0.021 0.12 8,654 0.96 
Trans-ancestry meta-analysis 0.87 0.033 0.005 1.8x10-9 147,633 0.80 
 
Locus: FES.  Lead SNP: rs12906125.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.69 0.020 0.006 0.00036 73,495 0.92 
Component 2: UKBB 0.67 0.025 0.006 1.1x10-5 67,786 N/A 
European ancestry meta-analysis 0.68 0.023 0.004 1.7x10-8 141,281 0.55 
Component 3: non-European ancestry 0.75 0.018 0.017 0.30 10,103 0.87 
Trans-ancestry meta-analysis 0.69 0.023 0.004 1.0x10-8 151,384 0.75 
 
Locus: IGF1R.  Lead SNP: rs7402982.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.43 0.022 0.005 4.9x10-5 71,637 0.24 
Component 2: UKBB 0.41 0.024 0.006 1.3x10-5 67,786 N/A 
European ancestry meta-analysis 0.43 0.023 0.004 2.3x10-9 139,423 0.83 
Component 3: non-European ancestry 0.35 0.020 0.017 0.23 10,103 0.61 
Trans-ancestry meta-analysis 0.42 0.023 0.004 1.1x10-9 149,526 0.61 
 
Locus: GPR139.  Lead SNP: rs1011939.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.31 0.022 0.006 0.00013 75,818 0.93 
Component 2: UKBB 0.28 0.022 0.006 0.00030 67,786 N/A 
European ancestry meta-analysis 0.30 0.022 0.004 1.3x10-7 143,604 0.97 
Component 3: non-European ancestry 0.57 0.047 0.015 0.0013 10,098 0.52 
Trans-ancestry meta-analysis 0.31 0.024 0.004 2.7x10-9 153,702 0.66 
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Locus: CLDN7.  Lead SNP: rs113086489.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.57 0.033 0.005 7.1x10-10 71,640 0.10 
Component 2: UKBB 0.55 0.028 0.005 2.6x10-7 67,786 N/A 
European ancestry meta-analysis 0.56 0.031 0.004 9.1x10-16 139,426 0.51 
Component 3: non-European ancestry 0.40 0.012 0.015 0.40 10,104 0.29 
Trans-ancestry meta-analysis 0.55 0.030 0.004 1.3x10-15 149,530 0.77 
 
Locus: SUZ12P1-CRLF3.  Lead SNP: rs144843919.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.97 0.036 0.018 0.0048 53,571 0.13 
Component 2: UKBB 0.96 0.087 0.015 1.0x10-8 67,786 N/A 
European ancestry meta-analysis 0.96 0.066 0.012 1.4x10-8 121,357 0.033 
Component 3: non-European ancestry 0.96 0.112 0.049 0.022 6,635 0.056 
Trans-ancestry meta-analysis 0.96 0.068 0.011 1.5x10-9 127,992 0.068 
 
Locus: SP6-SP2.  Lead SNP: rs12942207.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.31 0.025 0.006 2.2x10-5 71,635 0.85 
Component 2: UKBB 0.30 0.020 0.006 0.00063 67,786 N/A 
European ancestry meta-analysis 0.30 0.022 0.004 5.1x10-8 139,421 0.59 
Component 3: non-European ancestry 0.26 0.050 0.018 0.0053 8,654 0.98 
Trans-ancestry meta-analysis 0.30 0.024 0.004 3.0x10-9 148,075 0.75 
 
Locus: ACTL9.  Lead SNP: rs61154119.  Effect/other alleles: T/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.84 0.030 0.007 6.4x10-5 63,412 0.00014 
Component 2: UKBB 0.85 0.026 0.007 0.00050 67,786 N/A 
European ancestry meta-analysis 0.84 0.028 0.005 1.1x10-7 131,198 0.70 
Component 3: non-European ancestry 0.79 0.033 0.018 0.077 8,655 0.64 
Trans-ancestry meta-analysis 0.84 0.028 0.005 2.3x10-8 139,853 0.98 
 
Locus: PEPD.  Lead SNP: rs10402712.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.25 0.021 0.006 0.00033 71,642 0.23 
Component 2: UKBB 0.26 0.022 0.006 0.00042 67,786 N/A 
European ancestry meta-analysis 0.26 0.022 0.004 4.4x10-7 139,428 0.98 
Component 3: non-European ancestry 0.40 0.038 0.014 0.0086 10,102 0.89 
Trans-ancestry meta-analysis 0.27 0.023 0.004 2.3x10-8 149,530 0.72 
 
Locus: JAG1.  Lead SNP: rs6040076.  Effect/other alleles: C/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.48 0.023 0.005 3.1x10-5 71,638 0.82 
Component 2: UKBB 0.51 0.023 0.005 1.8x10-5 67,786 N/A 
European ancestry meta-analysis 0.49 0.023 0.004 2.0x10-9 139,424 0.96 
Component 3: non-European ancestry 0.69 -0.006 0.018 0.73 8,655 0.026 
Trans-ancestry meta-analysis 0.51 0.022 0.004 7.2x10-9 148,079 0.24 
 
Locus: C20orf203.  Lead SNP: rs28530618.  Effect/other alleles: A/G. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.50 0.032 0.005 5.0x10-9 70,376 0.45 
Component 2: UKBB 0.47 0.020 0.005 0.00015 67,786 N/A 
European ancestry meta-analysis 0.49 0.026 0.004 7.7x10-12 138,162 0.14 
Component 3: non-European ancestry 0.63 -0.011 0.016 0.50 10,102 0.25 
Trans-ancestry meta-analysis 0.50 0.024 0.004 8.4x10-11 148,264 0.18 
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Locus: MAFB.  Lead SNP: rs6016377.  Effect/other alleles: T/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.41 0.028 0.005 3.8x10-7 71,639 0.10 
Component 2: UKBB 0.45 0.020 0.006 0.00043 67,786 N/A 
European ancestry meta-analysis 0.43 0.024 0.004 9.5x10-10 139,425 0.29 
Component 3: non-European ancestry 0.74 0.025 0.018 0.17 10,103 0.26 
Trans-ancestry meta-analysis 0.45 0.024 0.004 3.7x10-10 149,528 0.27 
 
Locus: NRIP1.  Lead SNP: rs2229742.  Effect/other alleles: G/C. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.85 0.037 0.008 6.6x10-6 75,886 0.66 
Component 2: UKBB 0.90 0.034 0.009 9.1x10-5 67,786 N/A 
European ancestry meta-analysis 0.87 0.036 0.006 2.2x10-9 143,672 0.82 
Component 3: non-European ancestry 0.82 -0.085 0.044 0.052 9,264 0.72 
Trans-ancestry meta-analysis 0.87 0.034 0.006 1.5x10-8 152,936 0.092 
 
Locus: KREMEN1.  Lead SNP: rs134594.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.35 0.022 0.006 8.9x10-5 69,554 0.36 
Component 2: UKBB 0.35 0.023 0.006 3.2x10-5 67,786 N/A 
European ancestry meta-analysis 0.35 0.023 0.004 1.0x10-8 137,340 0.84 
Component 3: non-European ancestry 0.33 0.002 0.016 0.90 8,655 0.59 
Trans-ancestry meta-analysis 0.35 0.022 0.004 2.2x10-8 145,995 0.25 
 
Locus: SREBF2.  Lead SNP: rs62240962.  Effect/other alleles: C/T. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.91 0.054 0.010 2.6x10-8 68,286 0.69 
Component 2: UKBB 0.92 0.040 0.010 6.0x10-5 67,786 N/A 
European ancestry meta-analysis 0.91 0.047 0.007 9.7x10-12 136,072 0.30 
Component 3: non-European ancestry 0.97 0.07 0.048 0.15 7,815 0.028 
Trans-ancestry meta-analysis 0.92 0.047 0.007 3.7x10-12 143,887 0.69 
 
Locus: PLAC1.  Lead SNP: rs11096402.  Effect/other alleles: G/A. 
Analysis EAF β SE P-value N Q P-value 
Component 1: European ancestry 0.28 0.027 0.007 2.0x10-4 37,417 0.73 
Component 2: UKBB 0.24 0.028 0.006 1.8x10-6 57,620 N/A 
European ancestry meta-analysis 0.25 0.028 0.005 1.3x10-9 95,037 0.31 
Component 3: non-European ancestry N/A N/A N/A N/A N/A N/A 
Trans-ancestry meta-analysis N/A N/A N/A N/A N/A N/A 
PLAC1 result (on X chromosome) was not available in non-European ancestry studies. 






Supplementary Table 4. Summary statistics for lead SNPs attaining genome-wide significant evidence (P<5x10-8) of association with BW in 
European ancestry meta-analysis of up to 143,677 individuals and/or trans-ancestry meta-analysis of up to 153,781 individuals. 
 
Locus SNP Chr Position 
(b37, bp) 




Best proxy in HapMap 
Effect Other β (SE) P-value β (SE) P-value SNP EUR r2 




1.1x10-9 TA/EUR  No rs2744726 0.99 




1.3x10-12 TA/EUR  No rs905938 0.77 




1.5x10-9 TA/EUR  No rs17413015 0.97 




4.5x10-8 TA  No rs1387815 0.51 




6.2x10-11 TA  No rs718139 0.98 




7.3x10-11 EUR 0.94 No   




1.5x10-29 TA  Yes   




1.9x10-29 EUR 0.99 Yes   




1.2x10-8 TA  Yes   




1.3x10-8 EUR 0.99 Yes   




6.4x10-27 TA/EUR  No rs7613951 0.97 




6.1x10-22 Previous 0.85 Yes   




6.2x10-10 TA/EUR  No rs12496367 0.81 




1.3x10-42 TA  Yes   




2.9x10-41 EUR 0.92 Yes   




8.4x10-41 Previous 0.92 Yes   




1.3x10-15 TA  Yes   




1.3x10-15 EUR 0.97 Yes   










Alleles  EAF 
  




Best proxy in HapMap 
Effect Other β (SE) P-value β (SE) P-value SNP EUR r2 




1.3x10-12 TA  Yes   




2.3x10-12 EUR 0.88 No   




3.5x10-8 TA/EUR  Yes   




7.0x10-7 Previous 0.47 Yes   




1.3x10-9 TA  No rs2946164 0.97 




1.5x10-9 EUR 0.98 No   




9.7x10-29 TA/EUR  No rs7756992 0.97 




1.0x10-26 Previous 0.94 Yes   




1.2x10-8 TA  No rs806794 0.62 




1.1x10-8 TA  Yes   




1.4x10-8 EUR 0.95 No   




4.0x10-11 TA/EUR  Yes   
ESR1  
 




6.1x10-20 TA  No rs851977 0.99 




1.3x10-19 EUR 0.98 Yes   




5.0x10-9 TA  Yes   




3.8x10-8 EUR 0.83 Yes   




1.0x10-9 TA/EUR  No rs12540730 0.86 




1.0x10-8 TA/EUR  Yes   




1.4x10-26 TA/EUR  No rs2908277 0.096 




5.9x10-12 TA  No rs17401675 1 




1.3x10-11 EUR 0.78 No   
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Best proxy in HapMap 
(b37, bp) Effect Other  β (SE) P-value β (SE) P-value SNP EUR r2 




1.6x10-11 TA/EUR  Yes   




5.0x10-8 TA  Yes   




1.9x10-9 TA/EUR  Yes   




4.0x10-16 TA  No rs3824488 1 




1.1x10-15 EUR 1.00 No   




2.8x10-8 TA  Yes   




4.1x10-8 EUR 0.86 Yes   




5.4x10-9 TA  Yes rs1056567 0.87 




1.5x10-8 EUR 0.88 Yes   




1.2x10-12 TA  Yes   




1.5x10-11 EUR 0.91 Yes   




9.5x10-15 TA  No rs2497306 0.97 




1.4x10-14 EUR 0.90 Yes   




1.8x10-9 TA  No rs11191582 1 




5.6x10-9 EUR 1.00 No   




4.7x10-18 TA  Yes   




6.4x10-18 EUR 0.99 Yes   




2.6x10-14 Previous 0.99 Yes   




6.1x10-9 TA/EUR  Yes   




6.8x10-10 TA/EUR  No rs868332 0.49 










Chr Position Alleles EAF 
  




Best proxy in HapMap 
(b37, bp) Effect Other β (SE) P-value β (SE) P-value SNP EUR r2 




2.3x10-8 TA  Yes   




1.0x10-7 EUR  No rs4148656 0.67 




3.2x10-8 TA  Yes   




3.2x10-8 EUR 0.96 Yes   




2.0x10-33 TA/EUR  Yes   




7.1x10-32 Previous 0.93 Yes   




9.7x10-9 TA/EUR  Yes   




8.3x10-9 TA  Yes   




1.8x10-8 EUR 1.00 Yes   




2.2x10-8 TA  No rs9568028 0.88 




5.8x10-8 EUR 0.85 No   




1.8x10-9 TA/EUR  No rs944379 0.88 




1.0x10-8 TA/EUR  No rs6227 0.87 




1.1x10-9 TA/EUR  No rs8028620 0.55 




2.7x10-9 TA  No rs1858988 0.70 




1.3x10-15 TA/EUR  No rs5417 0.80 




1.5x10-9 TA/EUR  No rs8073965 0.22 




3.0x10-9 TA  No rs11079800 0.91 




2.1x10-8 EUR 0.94 No   




2.3x10-8 TA  No rs2967684 1 




2.3x10-8 TA  No rs17833935 0.54 
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Best proxy in HapMap 
(b37, bp) Effect Other β (SE) P-value β (SE) P-value SNP EUR r2 




7.2x10-9 TA/EUR  No rs2206815 0.85 




8.4x10-11 TA/EUR  No rs6057610 0.82 




3.7x10-10 TA/EUR  Yes   




1.5x10-8 TA/EUR  Yes   




2.2x10-8 TA/EUR  Yes   




3.7x10-12 TA/EUR  No rs10483213 0.70 
PLAC1 rs11096402 X 133,827,868 G A 0.28 0.028 
(0.005) 
1.3x10-9 N/A N/A EUR  Yes   
Chr, chromosome; bp, base pair; EAF, effect allele frequency; SE, standard error. 




Supplementary Table 5. Loci with multiple distinct association signals attaining genome-wide significance (P<5x10-8) in approximate 
conditional meta-analysis of 143,677 individuals of European ancestry, using 5,000 white British participants from UK BioBank as a 






Alleles EAF Unconditional 
meta-analysis 












β (SE) P-value Conditioned 
on 
β (SE) P-value 
SNP EUR r2 






2.2x10-14 0.019 No rs905938 0.77 






5.4x10-10 No rs12043212 0.93 






3.3x10-8 0.000 No rs4304152 0.57 






5.4x10-9 No rs1776877 0.95 






5.1x10-9 0.001 Yes   






1.2x10-18 No rs3824488 1.00 




Supplementary Table 6. Candidate gene(s) at birth weight loci. 
 




in the locusa 
Reports on eQTLb Literature search for nearby genes (300kb) 
Coding variants (EUR 
r2 with the lead SNP) 
WNT4-
ZBTB40  
rs2473248 1 22,536,643 
WNT4[P,N], 
CDC42[B] 
WNT4: Cerebellum and temporal cortex 




ZBTB7B  rs3753639 1 154,986,091 SHC1[B], S100A7[P]  
SHC1: The Shc adaptor proteins are key transducers of growth 
promotion and gene expression, and are phosphorylated by all 
known receptor tyrosine.  - 
FCGR2B  rs72480273 1 161,644,871 
ATF6[B], APOA2[P], 
FCGR2B[N] 
ATF6: Cerebellum and temporal cortex 
eQTL; FCGR2B: Whole blood, 
cerebellum and temporal cortex eQTL 
HSPA6: higher expression of HSPA6 in placental vascular disease 
(PVD) vs controls; HSPA6 encodes HSP70 which was found to be 
upregulated in PVD vs control placenta and microvascular 
endothelial cells. HSP70 mRNA and protein expression also 
correlated negatively with infant birth weight (PMID:18372927). - 
DTL rs61830764 1 212,289,976 DTL[N]   - 
ATAD2B  rs7575873 2 23,962,647 
ATAD2B[N], 
FKBP1B[P] 
PFN4: Lymphoblastoid eQTL 
 - 
EPAS1  rs1374204 2 46,484,205 RHOQ[B], SOCS5[P] 
EPAS1, PRKCE: Cerebellum and 
temporal cortex eQTL 
EPAS1: involved in the hypoxic response and is suggested to be 
responsible for the genetic adaptation of high-altitude hypoxia 
in Tibetans. PMID 25501874 found associations of 2 variants 
with BW in small sample-sized Tibetans. - 
PTH1R  rs2242116 3 46,941,116 
PTH1R[B,N], 
CCR1[P] 
CCDC12: Whole blood, cerebellum and 
temporal cortex eQTL  - 
ADCY5 rs11719201 3 123,068,744 
ADCY5[B,N], 
HCLS1[P] 
ADCY5: Cerebellum and temporal 
cortex eQTL (proxy SNP)  - 
CPA3  rs10935733 3 148,622,968 AGTR1[B,P] CPA3,CPB1: eQTL (proxy SNP) 
AGTR1 = angiotensin II receptor gene: good candidate as the 
protein mediates processes important for placentation. Levels 
of protein higher in umbilical cord and maternal peripheral 
blood in preeclampsia than in controls; levels of mRNA higher in 
placenta of preeclampsia than control pregnancies; birth weight 
negatively correlated with levels in cord (PMID 23302726). - 
CCNL1-LEKR1 rs13322435 3 156,795,468 LEKR1[N], IL12A[P] 
LEKR1: Temporal cortex eQTL; CCNL1: 
Whole blood, cerebellum and temporal 
cortex eQTL   - 
LCORL rs925098 4 17,919,811 LCORL[N], SLIT2[P] 
LCORL: Cerebellum and temporal cortex 
eQTL 
Adipose tissue and muscle expression in cattle of NCAPG and 
LCORL associated with feed intake and weight gain in cattle 
(these are in a QTL for body weight in cattle). - 
HHIP  rs6537307 4 145,601,863 
HHIP[N], 
ANAPC10[P] 
HHIP: Cerebellum and temporal cortex 
eQTL  - 
5q11.2 rs854037 5 57,091,783 ACTBL2[N], IL6ST[P]   - 
EBF1  rs7729301 5 157,886,953 EBF1[N,B], FABP6[P]   - 
CDKAL1 rs35261542 6 20,675,792 CDKAL1[B], SOX4[P] 
CDKAL1: Cerebellum and temporal 
cortex eQTL  - 
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in the locusa 
Reports on eQTLb Literature search for nearby genes (300kb) 
Coding variants (EUR 
r2 with the lead SNP) 









HMGA1: Cerebellum and temporal 
cortex eQTL 
 - 
L3MBTL3  rs1415701 6 130,345,835 
L3MBTL3[E,N], 
SAMD3[E], ENPP1[P] 
L3MBTL3, SAMD3: Whole blood, 
cerebellum and temporal cortex eQTLs  - 
ESR1  rs1101081 6 152,032,917 ESR1[N,B], LATS1[P] 
ESR1: Monocyte, cerebellum and 
temporal cortex eQTL (for proxy SNP)  - 
GNA12  rs798489 7 2,801,803 
GNA12[N,E], 
PDGFA[N] 
GNA12: Nerve tibial, lymphoblastid, 
whole blood, cerebellum and temporal 
cortex eQTL  - 
IGF2BP3  rs11765649 7 23,479,013 
IGF2BP3[N,B], 
NPY[P] 
CCDC126: lymphoblastoid eQTL 
 - 
TBX20  rs6959887 7 35,295,365 TBX20[N], SEPT7[P] 
TBX20: Cerebellum and temporal cortex 
eQTL  - 
YKT6-GCK rs138715366 7 44,246,271 YKT6[N], GCK[B]  
GCK mutations reduce birth weight and increase fasting glucose 
(Hattersley et al 1999, Nat Genet). - 
MLXIPL  rs62466330 7 73,056,805 MLXIPL[N], FZD9[P] 
MLXIPL: Cerebellum and temporal 
cortex eQTL (for proxy SNP)  - 
ANK1-NKX6-3  rs13266210 8 41,533,514 ANK1[N,B], SFRP1[P] 
ANK1: Cerebellum, temporal cortex and 
lung eQTL  - 
TRIB1 rs6989280 8 126,508,746 TRIB1[N], MYC[P] 
TRIB1: Cerebellum and temporal cortex 
eQTL  - 
SLC45A4  rs12543725 8 142,247,979 
SLC45A4[N,E], 
PTK2[B,P] 
SLC45A4: Whole blood, cerebellum and 
temporal cortex eQTL  - 
PTCH1  rs28510415 9 98,245,026 
PTCH1[N,B], 
FOXE1[P] 
PTCH1: Whole blood, cerebellum and 
temporal cortex eQTL (for proxy SNP) 
FANCC: mutations result in Fanconi anaemia (associated with 
low birth weight and shorter stature). - 
LPAR1  rs2150052 9 113,945,067 LPAR1[N,E,B,P] LPAR1: whole blood eQTL  - 
PHF19  rs7847628 9 123,631,225 C5[B], DAB2IP[P] 
C5: naïve monocyte, whole blood, 
cerebellum and temporal cortex eQTL  - 
STRBP  rs700059 9 125,824,055 STRBP[E], C5[P] 
STRBP: Whole blood, cerebellum and 
temporal cortex eQTL  - 
HHEX-IDE  rs61862780 10 94,468,643 IDE[B], PLCE1[P] 
HHEX: monocyte, whole blood, 
cerebellum and temporal cortex eQTL  - 
NT5C2 rs74233809 10 104,913,940 NT5C2[N], CHUK[P]  CYP17A1: mutation in maternal CYP17A1 is associated with 
small for gestational age (SGA) (PMID 14665706) - 
ADRB1 rs7076938 10 115,789,375 
ADRB1[N,C,B], 
AFAP1L2[P] 




PLEKHA1  rs2421016 10 124,167,512 
PLEKHA1[N,E], 
FGFR2[P] 
PLEKHA1: Whole blood, cerebellum and 
temporal cortex eQTL  - 
INS-IGF2  rs72851023 11 2,130,620 INS-IGF2[N,B,imp]   - 
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in the locusa 
Reports on eQTLb Literature search for nearby genes (300kb) 
Coding variants (EUR 
r2 with the lead SNP) 
MTNR1B  rs10830963 11 92,708,710 MTNR1B[N,B,P] 
MTNR1B: Cerebellum and temporal 
cortex eQTL  - 
APOLD1 rs11055034 12 12,890,626 
CDKN1B[B,E,P], 
HEBP1[B] 
CDKN1B: Cerebellum and temporal 
cortex eQTL  - 
ABCC9  rs139975827 12 22,068,161 ABCC9[N], KRAS[P]   - 
ITPR2 rs12823128 12 26,872,730 ITPR2[N,B] 
ITPR2: Cerebellum and temporal cortex 
eQTL  - 
HMGA2 rs1351394 12 66,351,826 
HMGA2[N,B], 
IRAK3[P] 
HMGA2: Cerebellum and temporal 
cortex eQTL 
HMGA2: 12q14 microdeletion syndrome implicates HMGA2 as 
causal to height (PMID: 17220210 and 19298872). - 
IGF1  rs7964361 12 102,994,878 IGF1[N,B,P]   - 





RB1 rs2854355 13 48,882,363 
RB1[N,B,P,imp], 
LPAR6[imp,B] 
RB1: Whole blood, cerebellum and 
temporal cortex eQTL  - 
RNF219-AS1  rs1819436 13 78,580,283 EDNRB[B,P] 
EDNRB: Monocyte, cerebellum and 
temporal cortex eQTL (for proxy SNP)  - 
FES  rs12906125 15 91,427,612 FES[N,E], MESP1[P] 
FES: Thyroid, whole blood, cerebellum, 
temporal cortex and tibial nerve eQTL 
FURIN: a ubiquitous proprotein convertase, the major 
processing enzyme of the secretory pathway. It is involved in 
processing proinsulin to insulin, and in processing proIGF2 
(PMID 9660813). - 
IGF1R  rs7402982 15 99,193,269 IGF1R[B]   - 





CLDN7  rs113086489 17 7,171,356 
SLC2A4[B], 
POLR2A[S], DVL2[P] 
SLC2A4: Cerebellum and temporal 
cortex eQTL; DVL2: monocyte, whole 
blood, cerebellum and temporal cortex 
eQTL (for proxy SNP) 
SLC2A4 (GLUT4): an insulin responsive glucose transporter. 
PMID 24062248 showed lower mRNA in preadipocytes from 
LBW vs NBW. Protein level of SLCA24 was lower in adipose 
tissue of LBW men compared to NMW (PMID 17063325). - 
SUZ12P1-
CRLF3  
rs144843919 17 29,037,339 SUZ12P1[N]  
 - 
SP6-SP2 rs12942207 17 45,968,294 SP2[N], NGFR[P] 
SP2: Whole blood, cerebellum and 
temporal cortex eQTL (for proxy SNP)  - 
ACTL9  rs61154119 19 8,787,750 ACTL9[N], INSR[P]   - 
PEPD rs10402712 19 33,926,013 CEBPA[B]  
CEBPA: an adipogenic transcription factor involved in adipocyte 
differentiation. Expression levels lower in smaller pig fetuses 
(PMID 21354690). - 
JAG1  rs6040076 20 10,658,882 JAG1[N], MKKS[P] 
JAG1: Cerebellum and temporal cortex 
eQTL (proxy SNP) 
JAG1 is a ligand that interacts with receptors in the notch 
signalling pathway. Notch pathway plays an important role 
during placental development; notch pathway downregulation 
is associated with preeclampsia, and specifically JAG1 mRNA 
levels downregulated in preeclampsia placental samples vs 
controls (PMID 25962154). - 
C20orf203  rs28530618 20 31,275,581 
BAK1P1[E], 
FOXS1[P] 
BAK1P1: thyroid eQTL (for proxy SNP)  
 - 
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in the locusa 
Reports on eQTLb Literature search for nearby genes (300kb) 
Coding variants (EUR 
r2 with the lead SNP) 
MAFB rs6016377 20 39,172,728 MAFB[N], PLCG1[P] 
MAFB: Cerebellum and temporal cortex 
eQTL (for proxy SNP) 
Lots of literature on importance of MAFB in transcriptional 
regulation in embryonic islets, e.g. analysis of Mafa(-/-) and 
pancreas-specific Mafa(∆panc) deletion mutant mice 
demonstrated a primary role for MafA in adult β-cell activity, 
different from the embryonic importance of MafB (PMID 
24520122). - 
NRIP1 rs2229742 21 16,339,172 
NRIP1[N,C], 
SAMSN1[P] 




lead SNP, damaging) 
KREMEN1  rs134594 22 29,468,456 
KREMEN1[N,E], 
YWHAH[P] 
KREMEN1: Monocyte, heart, whole 









PLAC1 rs11096402 X 133,827,868 PLAC1[N]  
PLAC1 shows placenta-specific expression in human (PMID: 
10995572). A mutant mouse model showed PLAC1 as a 
paternally imprinted, X-linked gene essential for normal 
placental and embryonic development (PMID: 22729990).  - 
aB = biological candidate, C = coding variant, E = eQTL (from GTEx), N=nearest, P = best ranked gene in PPI network, imp = imprinted gene. 
beQTL reported from GTEx v4, GEUVADIS, and 11 other studies for the lead variant. When there was no eQTL report for the lead variant, eQTL reports for the proxy SNPs (r2>0.8 




Supplementary Table 7. Summary of 99% credible sets at 62 distinct autosomal association signals. 
 




99% credible set 
Variants Distance (bp) Interval (bp) 
WNT4-ZBTB40  rs2473248 1 22,536,643 7.68 7 17,534 22,536,643-22,554,176 
ZBTB7B  rs3753639 1 154,986,091 12.19 6 22,088 154,984,363-155,006,450 
 rs4330912 1 155,969,428 7.93 45 403,839 155,612,197-156,016,035 
FCGR2B  rs72480273 1 161,644,871 7.48 37 173,221 161,500,712-161,673,932 
DTL rs61830764 1 212,289,976 6.02 56 702,234 211,830,044-212,532,277 
ATAD2B  rs7575873 2 23,962,647 8.87 234 477,824 23,887,437-24,365,260 
EPAS1  rs1374204 2 46,484,205 27.22 4 695 46,484,188-46,484,882 
PTH1R  rs2242116 3 46,941,116 6.65 54 243,837 46,925,539-47,169,375 
ADCY5  rs11719201 3 123,068,744 24.38 6 16,621 123,065,778-123,082,398 
CPA3  rs10935733 3 148,622,968 7.91 80 33,654 148,591,725-148,625,378 
CCNL1-LEKR1  rs13322435 3 156,795,468 40.24 11 3,265 156,795,468-156,798,732 
LCORL  rs925098 4 17,919,811 13.56 15 123,806 17,901,679-18,025,484 
HHIP  rs6537307 4 145,601,863 10.43 43 137,679 145,520,608-145,658,286 
5q11.2 rs854037 5 57,091,783 5.77 63 276,269 56,906,160-57,182,428 
EBF1  rs7729301 5 157,886,953 7.62 50 77380 157,884,706-157,962,085 
CDKAL1  rs35261542 6 20,675,792 26.41 7 14,242 20,673,880-20,688,121 
HIST1H2BE rs9379832 6 26,186,200 6.64 5 26,542 26,180,634-26,207,175 
HMGA1  rs9368777 6 33,788,637 6.20 91 570,460 33,292,543-33,863,002 
 rs1187118 6 34,169,020 6.94 27 148,294 34,095,696-34,243,989 
L3MBTL3  rs1415701 6 130,345,835 9.03 2 4,601 130,341,235-130,345,835 
ESR1  rs1101081 6 152,032,917 17.69 14 20,968 152,029,556-152,050,523 
GNA12  rs798489 7 2,801,803 7.01 114 160,777 2,752,152-2,912,928 
IGF2BP3  rs11765649 7 23,479,013 7.58 23 111,149 23,474,687-23,585,835 
TBX20  rs6959887 7 35,295,365 6.75 113 109,117 35,196,208-35,305,324 
YKT6-GCK rs138715366 7 44,246,271 24.10 1 1 44,246,271-44,246,271 
MLXIPL  rs62466330 7 73,056,805 9.60 102 221,896 72,836,230-73,058,025 
ANK1-NKX6-3  rs13266210 8 41,533,514 9.22 17 28,742 41,508,577-41,537,318 
TRIB1 rs6989280 8 126,508,746 5.69 39 411,117 126,114,947-126,526,063 
SLC45A4  rs12543725 8 142,247,979 7.18 10 13,200 142,239,381-142,252,580 
PTCH1  rs12551019 9 96,949,079 6.96 40 652,934 96,900,505-97,553,438 
 rs3780573 9 98,239,503 16.44 23 53,294 98,212,608-98,265,901 
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Locus Index variant Chr Position MANTRA 
log10BF 
99% credible set 
(b37, bp) Variants Distance (bp) Interval (bp) 
LPAR1  rs2150052 9 113,945,067 6.29 60 214,738 113,828,811-114,043,548 
PHF19  rs7847628 9 123,631,225 6.95 5 90,924 123,631,225-123,722,148 
STRBP  rs700059 9 125,824,055 10.35 135 432,744 125,605,840-126,038,583 
HHEX-IDE  rs61862780 10 94,468,643 12.40 31 134,694 94,358,023-94,492,716 
NT5C2 rs74233809 10 104,913,940 7.25 98 404,547 104,655,350-105,059,896 
ADRB1  rs7076938 10 115,789,375 15.69 4 9,521 115,789,375-115,798,895 
PLEKHA1  rs2421016 10 124,167,512 6.90 26 70,596 124,127,990-124,198,585 
INS-IGF2  rs72851023 11 2,130,620 7.89 48 145,434 2,078,742-2,224,175 
MTNR1B  rs10830963 11 92,708,710 5.78 52 499,464 92,225,858-92,725,321 
APOLD1 rs11055034 12 12,890,626 6.33 13 42,180 12,849,241-12,891,420 
ABCC9  rs139975827 12 22,068,161 5.64 72 133,773 22,027,182-22,160,954 
ITPR2 rs12823128 12 26,872,730 6.12 114 291,548 26,759,026-27,050,573 
HMGA2  rs1351394 12 66,351,826 30.74 7 32,282 66,343,810-66,376,091 
IGF1  rs7964361 12 102,994,878 6.71 42 213,557 102,867,636-103,081,192 
LINC00332 rs2324499 13 40,662,001 6.83 41 95,318 40,583,503-40,678,820 
RB1 rs2854355 13 48,882,363 6.23 143 403,044 48,797,661-49,200,704 
RNF219-AS1  rs1819436 13 78,580,283 7.44 105 220,228 78,443,297-78,663,524 
FES  rs12906125 15 91,427,612 6.68 24 36,382 91,404,705-91,441,086 
IGF1R  rs7402982 15 99,193,269 7.59 5 15,682 99,177,595-99,193,276 
GPR139 rs1011939 16 19,992,996 7.20 55 53,120 19,992,996-20,461,115 
CLDN7  rs113086489 17 7,171,356 13.41 29 84,570 7,101,292-7,185,861 
SUZ12P1-CRLF3  rs144843919 17 29,037,339 7.60 21 520,396 28,780,178-29,300,573 
SP6-SP2 rs12942207 17 45,968,294 7.04 21 90,685 45,940,310-46,030,994 
ACTL9 rs61154119 19 8,787,750 6.24 21 4,455 8,785,744-8,790,198 
PEPD rs10402712 19 33,926,013 6.40 35 218,599 33,784,657-34,003,255 
JAG1  rs6040076 20 10,658,882 6.72 43 164,577 10,539,775-10,704,351 
C20orf203  rs28530618 20 31,275,581 8.69 63 114,192 31,214,234-31,328,425 
MAFB rs6016377 20 39,172,728 8.15 33 72,001 39,144,286-39,216,286 
NRIP1 rs2229742 21 16,339,172 6.69 4 85,250 16,339,172-16,424,421 
KREMEN1  rs134594 22 29,468,456 6.41 56 52,177 29,461,150-29,513,326 
SREBF2  rs62240962 22 42,259,524 10.01 4 189,151 42,070,374-42,259,524 
Chr, chromosome; bp, base pair; BF, Bayes factor.
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Supplementary Table 8. BW credible set enrichment for DNaseI hypersensitive sites. 
 
(a) 128 cell-type DHS annotation and 4 genic annotation tested for enrichment individually 





iPS_6_9 -20.00 0.35 1.74 Stem cell Stem cell 
iPS_4_7 -20.00 0.82 2.04 Stem cell Stem cell 
iPS_19_7 -1.22 0.96 2.09 Stem cell Stem cell 
iPS_19_11 -1.40 0.80 1.93 Stem cell Stem cell 
hESCT0 -0.10 1.26 2.16 Stem cell Stem cell 
HESC -20.00 0.21 1.79 Stem cell Stem cell 
NPC 0.94 2.14 2.99 Brain Progenitor cell 
HMVEC_dNeo 0.24 1.62 2.54 Neonatal blood vessel Neonatal 
HMVEC_dLyNeo 0.48 1.71 2.58 Neonatal blood vessel Neonatal 
HMVEC_dBlNeo -0.82 1.00 2.01 Neonatal blood vessel Neonatal 
NHDF_Neo 1.22 2.29 3.12 Skin Neonatal 
fThymus 0.88 1.94 2.75 Foetal thymus Foetal 
fTestes 0.88 1.97 2.79 Foetal testes Foetal 
fStomach 0.40 1.63 2.50 Foetal stomach Foetal 
fSpleen 0.75 1.86 2.68 Foetal spleen Foetal 
fSpinal_cord 0.52 1.58 2.38 Foetal skin Foetal 
fSkin_fibro_upper_back -0.86 1.43 2.44 Foetal skin Foetal 
fSkin_fibro_scalp -4.83 1.03 2.17 Foetal skin Foetal 
fSkin_fibro_leg_R_quad -20.00 0.84 2.11 Foetal skin Foetal 
fSkin_fibro_leg_L_quad -0.89 1.23 2.25 Foetal skin Foetal 
fSkin_fibro_bicep_R -20.00 0.73 2.05 Foetal skin Foetal 
fSkin_fibro_bicep_L -20.00 1.09 2.24 Foetal skin Foetal 
fSkin_fibro_back -20.00 0.04 1.75 Foetal skin Foetal 
fSkin_fibro_abdomen -3.50 1.30 2.41 Foetal skin Foetal 
fSkin -20.00 1.13 2.31 Foetal skin Foetal 
fPlacenta 0.80 1.72 2.49 Foetal placenta Foetal 
fMuscle_upper_trunk 0.70 1.74 2.55 Foetal muscle Foetal 
fMuscle_upper_limb_sk -0.08 1.43 2.35 Foetal muscle Foetal 
fMuscle_upper_back 0.48 1.70 2.54 Foetal muscle Foetal 
fMuscle_trunk 0.63 1.72 2.54 Foetal muscle Foetal 
fMuscle_lower_limb 0.53 1.53 2.33 Foetal muscle Foetal 
fMuscle_leg 0.22 1.60 2.49 Foetal muscle Foetal 
fMuscle_back 0.34 1.37 2.17 Foetal muscle Foetal 
fMuscle_arm 0.46 1.73 2.60 Foetal muscle Foetal 
fLung_R 0.76 1.84 2.65 Foetal lung Foetal 
fLung_L 0.09 1.50 2.41 Foetal lung Foetal 
fLung -1.03 1.34 2.42 Foetal lung Foetal 
fKidney_renal_pelvis_R 1.23 2.12 2.87 Foetal kidney Foetal 
fKidney_renal_pelvis_L 0.51 1.62 2.45 Foetal kidney Foetal 
fKidney_renal_pelvis 0.60 1.69 2.52 Foetal kidney Foetal 
fKidney_renal_cortex_R 0.03 1.44 2.35 Foetal kidney Foetal 
fKidney_renal_cortex_L 0.91 1.88 2.67 Foetal kidney Foetal 
fKidney_R 0.52 1.63 2.45 Foetal kidney Foetal 
fKidney_L 0.70 1.81 2.65 Foetal kidney Foetal 
fKidney 0.42 1.65 2.51 Foetal kidney Foetal 
fIntestine_Sm -0.17 1.29 2.22 Foetal intestine Foetal 
fIntestine_Lg 0.25 1.63 2.55 Foetal intestine Foetal 
fHeart 0.21 1.56 2.45 Foetal heart Foetal 
fBrain 0.65 1.90 2.78 Foetal brain Foetal 
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fAdrenal 0.54 1.69 2.52 Foetal adrenal Foetal 
WI_38_TAM -3.99 0.83 1.95 Embryonic Embryonic 
WI_38 -20.00 0.43 1.87 Embryonic Embryonic 
Trophoblast -20.00 1.21 2.36 Embryonic Embryonic 
Mesendoderm -0.52 1.15 2.15 Embryonic Embryonic 
Skin_Melanocytes -0.05 1.40 2.33 Skin Adult 
Skin_Keratinocytes -20.00 0.84 2.00 Skin Adult 
Skin_Fibroblasts 0.81 1.81 2.64 Skin Adult 
NHEK -20.00 0.57 1.98 Skin Adult 
NHDF_Ad -0.75 1.09 2.09 Skin Adult 
BJ -0.05 1.65 2.64 Skin Adult 
AG10803 -0.12 1.50 2.46 Skin Adult 
AG09309 -20.00 1.03 2.20 Skin Adult 
AG04449 -0.32 1.50 2.47 Skin Adult 
PrEC -20.00 0.83 2.13 Prostate Adult 
LNCap -20.00 1.28 2.42 Prostate Adult 
SkMC -0.82 1.33 2.38 Muscle Adult 
HSMM_D -20.00 0.66 1.83 Muscle Adult 
HSMM -20.00 -1.29 1.31 Muscle Adult 
NHLF -2.24 0.96 2.08 Lung Adult 
IMR90 -20.00 0.61 1.93 Lung Adult 
HPF -1.69 1.00 2.10 Lung Adult 
AG04450 0.03 1.60 2.56 Lung Adult 
HRGEC -0.64 1.57 2.60 Kidney Adult 
HCM -20.00 0.79 1.99 Heart Adult 
HCFaa -0.48 1.25 2.25 Heart Adult 
HCF -2.09 1.13 2.20 Heart Adult 
HGF 0.49 1.88 2.79 Gingival Adult 
AG09319 -0.49 1.54 2.56 Gingival Adult 
HFF_MyC -1.06 1.16 2.21 Foreskin Adult 
HFF 0.51 1.74 2.62 Foreskin Adult 
HConF -20.00 0.94 2.12 Eye Adult 
SAEC -20.00 0.92 2.11 Epithelium Adult 
RPTEC -20.00 -0.11 1.55 Epithelium Adult 
HRPEpiC -20.00 0.20 1.67 Epithelium Adult 
HRE -1.34 1.17 2.20 Epithelium Adult 
HRCE -20.00 0.82 2.02 Epithelium Adult 
HPdLF -20.00 0.55 1.91 Epithelium Adult 
HNPCEpiC -0.11 1.42 2.36 Epithelium Adult 
HIPEpiC -0.16 1.38 2.32 Epithelium Adult 
HEEpiC -0.05 1.51 2.45 Epithelium Adult 
HCPEpiC 0.06 1.53 2.45 Epithelium Adult 
HAEpiC -0.87 1.21 2.23 Epithelium Adult 
HVMF -0.07 1.53 2.49 Connective Adult 
vHMEC -0.13 1.36 2.29 Breast Adult 
HMF -0.37 1.35 2.31 Breast Adult 
HMEC 0.27 1.69 2.60 Breast Adult 
NHA -1.48 1.16 2.22 Brain Adult 
HAsp -20.00 0.63 1.91 Brain Adult 
HAh -20.00 0.59 1.80 Brain Adult 
HAc -20.00 0.63 1.97 Brain Adult 
HUVEC -0.57 1.36 2.38 Blood vessel Adult 
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HPAF -20.00 0.95 2.08 Blood vessel Adult 
HPAEC -1.23 1.34 2.44 Blood vessel Adult 
HMVEC_LLy -0.39 1.32 2.34 Blood vessel Adult 
HMVEC_LBl -4.39 0.70 1.90 Blood vessel Adult 
HMVEC_dLyAd -20.00 1.02 2.24 Blood vessel Adult 
HMVEC_dBlAd 0.03 1.46 2.38 Blood vessel Adult 
HMVEC_dAd -0.79 1.37 2.44 Blood vessel Adult 
HBMEC -1.98 0.88 1.96 Blood vessel Adult 
AoAF -20.00 0.73 1.92 Blood vessel Adult 
hTH2 0.28 1.54 2.43 Blood Adult 
hTH17 -20.00 1.00 2.39 Blood Adult 
hTH1 0.19 1.61 2.53 Blood Adult 
H9_P42 -0.80 1.24 2.27 Blood Adult 
H1_P18 -0.07 1.40 2.35 Blood Adult 
GM12878 -0.72 1.24 2.30 Blood Adult 
GM12865 -20.00 0.73 2.07 Blood Adult 
GM12864 -20.00 0.85 2.10 Blood Adult 
GM06990 -20.00 0.98 2.19 Blood Adult 
CD8 0.34 1.73 2.66 Blood Adult 
CD56 -1.01 1.06 2.13 Blood Adult 
CD4 -0.49 1.28 2.29 Blood Adult 
CD34 -0.15 1.50 2.49 Blood Adult 
CD3_CordBlood -1.52 1.56 2.69 Blood Adult 
CD3 -2.48 1.09 2.30 Blood Adult 
CD20 -2.52 0.90 2.01 Blood Adult 
CD19 0.29 1.71 2.66 Blood Adult 
CD14 -0.70 1.07 2.10 Blood Adult 
TSS -0.87 1.37 2.42 Genic Genic 
3UTR -20.00 1.04 2.47 Genic Genic 
5UTR -47.50 -2.00 2.14 Genic Genic 
CDS -2.08 1.03 2.48 Genic Genic 
 
(b) Six categorical fields from ENCODE tested for enrichment in a joint model 
Annotation Lower 95% CIa Effecta Upper 95% CIa 
Neonatal DHS 0.60 1.59 2.40 
Foetal DHS 0.57 1.43 2.37 
Genic -0.85 0.63 1.61 
Stem_cell DHS -1.35 0.09 1.04 
Adult DHS -1.12 -0.26 0.62 
Embryonic DHS -3.95 -1.49 -0.39 
aEstimated effects of enrichment and 95% CI are natural log transformed. We considered an annotation 
enriched if the 95% CI of the estimated effects of enrichment did not overlap zero.
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Supplementary Table 9. Genetic variance explained.  
 
Study N By 62 known and 
novel SNPs 





HAPO 1338 0.020 0.011 0.013 0.010 
NFBC1966 5402 0.029 0.007 0.020 0.006 
Generation R 2537 0.049 0.013 0.026 0.009 
SE, standard error. HAPO study is independent of the birth weight meta-analysis whilst NFBC1966 and 
Generation R (European component) are part of the meta-analysis.     
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Supplementary Table 10. Look-up of maternal genotype effect on offspring BW (unadjusted for foetal genotype) in up to 68,254 mothers for 
the 60 BW loci detected in foetal birth weight GWAS. 
 







Betaa Effect Other β SE EAF β SE P-value N 
WNT4-ZBTB40  rs2473248 C T 0.033 0.006 0.88 0.013 0.010 0.20 48,632 0.020 
ZBTB7B  rs3753639 C T 0.031 0.004 0.25 0.017 0.008 0.03 48,632 0.014 
FCGR2B  rs72480273 C A 0.031 0.005 0.19 0.013 0.008 0.11 48,632 0.018 
DTL rs61830764 A G 0.022 0.004 0.37 -0.002 0.007 0.76 48,632 0.020 
ATAD2B  rs7575873 A G 0.038 0.004 0.87 -0.011 0.010 0.27 48,632 0.028 
EPAS1  rs1374204 T C 0.047 0.004 0.69 0.024 0.006 5.6x10-5 68,252 0.023 
PTH1R  rs2242116 A G 0.022 0.004 0.37 0.019 0.006 9.3x10-4 67,542 0.004 
ADCY5  rs11719201 T C 0.046 0.004 0.25 -0.001 0.008 0.85 48,632 0.045 
CPA3  rs10935733 T C 0.022 0.004 0.40 0.015 0.007 0.02 48,632 0.007 
CCNL1-LEKR1 rs13322435 A G 0.053 0.004 0.59 0.026 0.006 9.5x10-6 68,250 0.027 
LCORL  rs925098 G A 0.034 0.004 0.28 0.025 0.006 2.9x10-5 68,254 0.009 
HHIP  rs6537307 G A 0.025 0.004 0.49 0.019 0.005 4.4x10-4 68,247 0.006 
5q11.2  rs854037 A G 0.027 0.005 0.80 0.009 0.007 0.18 68,219 0.018 
EBF1  rs7729301 A G 0.024 0.004 0.74 0.039 0.007 8.9x10-8 48,632 -0.015 
CDKAL1  rs35261542 C A 0.044 0.004 0.74 0.004 0.007 0.60 48,632 0.040 
HIST1H2BE rs9379832 A G 0.023 0.004 0.73 0.008 0.007 0.30 48,632 0.015 
HMGA1  rs7742369 G A 0.028 0.005 0.19 0.017 0.007 0.01 68,253 0.011 
L3MBTL3  rs1415701 G A 0.025 0.004 0.73 0.037 0.006 3.7x10-9 66,897 -0.012 
ESR1  rs1101081 C T 0.038 0.004 0.72 0.021 0.007 3.8x10-3 48,632 0.017 
GNA12  rs798489 C T 0.023 0.004 0.72 0.023 0.006 1.6x10-4 68,253 0.001 
IGF2BP3  rs11765649 T C 0.027 0.004 0.74 0.015 0.007 0.04 48,632 0.012 
TBX20  rs6959887 A G 0.023 0.004 0.61 0.009 0.006 0.10 68,232 0.014 
YKT6-GCK rs138715366 C T 0.241 0.023 0.99 0.137 0.038 2.8x10-4 48,632 0.104 
MLXIPL rs62466330 C T 0.051 0.011 0.07 0.022 0.013 0.08 48,632 0.029 
ANK1-NKX6-3  rs13266210 A G 0.031 0.005 0.78 0.005 0.007 0.43 68,252 0.026 
TRIB1 rs6989280 G A 0.022 0.004 0.72 0.020 0.006 1.3x10-3 67,520 0.003 
SLC45A4  rs12543725 G A 0.023 0.004 0.58 0.021 0.005 1.4x10-4 68,222 0.002 
PTCH1  rs28510415 G A 0.056 0.007 0.09 0.034 0.011 2.2x10-3 48,632 0.022 
LPAR1  rs2150052 T A 0.021 0.004 0.50 0.017 0.005 1.4x10-3 68,245 0.004 
PHF19  rs7847628 G A 0.023 0.004 0.68 0.009 0.007 0.20 48,632 0.014 
STRBP  rs700059 G A 0.033 0.005 0.16 0.018 0.008 0.02 68,251 0.016 
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Betaa Effect Other β SE EAF β SE P-value N 
HHEX-IDE  rs61862780 T C 0.028 0.004 0.49 -0.004 0.006 0.55 48,632 0.024 
NT5C2 rs74233809 C T 0.037 0.007 0.08 0.005 0.012 0.70 48,632 0.032 
ADRB1  rs7076938 T C 0.036 0.004 0.73 0.010 0.006 0.09 68,254 0.026 
PLEKHA1  rs2421016 T C 0.021 0.004 0.48 0.016 0.005 3.3x10-3 68,253 0.005 
INS-IGF2  rs72851023 T C 0.048 0.008 0.08 0.015 0.012 0.24 48,632 0.033 
MTNR1B  rs10830963 G C 0.023 0.004 0.29 0.048 0.006 5.1x10-15 67,603 -0.025 
APOLD1 rs11055034 C A 0.022 0.004 0.71 0.002 0.006 0.74 67,597 0.020 
ABCC9  rs139975827 G A 0.027 0.007 0.63 -0.010 0.007 0.13 48,632 0.017 
ITPR2 rs12823128 T C 0.021 0.004 0.53 0.009 0.005 0.08 68,187 0.012 
HMGA2  rs1351394 T C 0.044 0.004 0.49 0.034 0.005 1.4x10-10 68,247 0.010 
IGF1  rs7964361 A G 0.039 0.007 0.10 0.018 0.010 0.06 68,251 0.021 
LINC00332 rs2324499 G C 0.022 0.004 0.68 0.012 0.006 0.05 68,213 0.011 
RB1 rs2854355 G A 0.023 0.004 0.26 0.017 0.007 0.03 48,632 0.007 
RNF219-AS1  rs1819436 C T 0.033 0.006 0.88 0.007 0.010 0.50 48,632 0.026 
FES  rs12906125 G A 0.023 0.004 0.68 0.029 0.007 1.8x10-5 48,632 -0.006 
IGF1R  rs7402982 A G 0.023 0.004 0.41 0.021 0.007 1.7x10-3 48,632 0.002 
GPR139 rs1011939 G A 0.022 0.004 0.28 0.007 0.007 0.34 48,632 0.015 
CLDN7  rs113086489 T C 0.031 0.004 0.54 0.022 0.007 7.7x10-4 48,632 0.009 
SUZ12P1-CRLF3  rs144843919 G A 0.066 0.012 0.96 0.041 0.018 0.02 48,632 0.025 
SP6-SP2 rs12942207 C T 0.022 0.004 0.30 0.010 0.007 0.14 48,632 0.012 
ACTL9 rs61154119 T G 0.028 0.005 0.85 0.047 0.009 1.5x10-7 48,632 -0.019 
PEPD rs10402712 A G 0.022 0.004 0.26 -0.002 0.007 0.76 48,632 0.020 
JAG1  rs6040076 C G 0.023 0.004 0.51 0.015 0.007 0.02 48,632 0.008 
C20orf203  rs28530618 A G 0.026 0.004 0.47 0.003 0.006 0.62 48,632 0.023 
MAFB rs6016377 T C 0.024 0.004 0.45 0.005 0.006 0.35 67,909 0.019 
NRIP1 rs2229742 G C 0.036 0.006 0.88 0.018 0.009 0.04 68,155 0.018 
KREMEN1  rs134594 C T 0.023 0.004 0.36 0.004 0.006 0.53 66,634 0.020 
SREBF2  rs62240962 C T 0.047 0.007 0.92 0.027 0.012 0.02 48,632 0.020 
PLAC1 rs11096402 G A 0.028 0.005 0.24 0.001 0.003 0.82 45,353 0.027 
SE, standard error, EAF, effect allele frequency. The lead SNPs at MTNR1B, HMGA2 and L3MBTL3 attained genome-wide significance in the maternal, as well as the foetal 
GWAS. aFoetal GWAS effect size subtracted from maternal GWAS effect size: 55/60 beta values were more positive in the foetal GWAS (aligned to BW-raising allele) than in 
the maternal GWAS (2-tailed binomial sign test P=1x10-11).  
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Supplementary Table 11. Maternal and foetal conditional analyses in 12,909 mother-child pairs. 
 
Locus Index variant EA/
NEA 
Maternal effect on offspring birth weight Foetal effect on birth weight 
Unadjusted Adjusted for foetal genotype Unadjusted Adjusted for maternal genotype 
β SE P-value β SE P-value β SE P-value β SE P-value 
WNT4-ZBTB40 rs2473248 C/T 0.004 0.018 0.82 -0.006 0.020 0.76 0.033 0.018 0.06 0.039 0.020 0.05 
ZBTB7B rs3753639 C/T 0.022 0.015 0.16 -0.005 0.017 0.79 0.060 0.016 9.8x10-5 0.060 0.018 5.7x10-4 
FCGR2B rs72480273 C/A 0.034 0.017 0.05 0.018 0.019 0.34 0.042 0.017 0.01 0.031 0.019 0.11 
DTL rs61830764 A/G 0.026 0.014 0.06 0.016 0.016 0.31 0.029 0.014 0.04 0.027 0.016 0.09 
ATAD2B rs7575873 A/G 0.018 0.019 0.35 0.007 0.022 0.74 0.042 0.019 0.03 0.047 0.022 0.03 
EPAS1 rs1374204 T/C 0.032 0.013 0.02 0.008 0.015 0.60 0.056 0.013 2.6x10-5 0.047 0.015 1.9x10-3 
PTH1R rs2242116 A/G 0.025 0.013 0.05 0.031 0.015 0.03 0.002 0.013 0.86 -0.013 0.014 0.38 
ADCY5 rs11719201 T/C 0.000 0.015 1.00 -0.025 0.017 0.15 0.057 0.015 2.2x10-4 0.075 0.017 1.5x10-5 
CPA3 rs10935733 T/C -0.004 0.013 0.73 -0.006 0.014 0.66 0.007 0.013 0.57 0.013 0.014 0.36 
CCNL1-LEKR1 rs13322435 A/G 0.028 0.013 0.03 -0.015 0.014 0.31 0.091 0.013 7.9x10-13 0.097 0.014 9.7x10-12 
LCORL rs925098 G/A 0.012 0.014 0.39 -0.017 0.016 0.29 0.057 0.014 3.1x10-5 0.060 0.015 1.0x10-4 
HHIP rs6537307 G/A 0.028 0.013 0.03 0.003 0.014 0.85 0.057 0.013 1.1x10-5 0.057 0.015 7.8x10-5 
5q11.2 rs854037 A/G 0.019 0.015 0.20 0.016 0.017 0.35 0.022 0.015 0.15 0.011 0.017 0.52 
EBF1 rs7729301 A/G 0.036 0.014 8.8x10-3 0.040 0.015 9.6x10-3 0.024 0.014 0.08 0.010 0.016 0.52 
CDKAL1 rs35261542 C/A 0.003 0.014 0.81 -0.028 0.016 0.07 0.057 0.014 4.3x10-5 0.071 0.016 6.1x10-6 
HIST1H2BE rs9379832 A/G -0.005 0.014 0.74 -0.012 0.016 0.45 0.022 0.014 0.12 0.026 0.016 0.10 
HMGA1 rs7742369 G/A 0.027 0.015 0.08 0.006 0.017 0.72 0.043 0.015 4.9x10-3 0.035 0.017 0.04 
L3MBTL3 rs1415701 G/A 0.035 0.014 0.01 0.019 0.016 0.22 0.052 0.014 2.7x10-4 0.041 0.016 0.01 
ESR1 rs1101081 C/T 0.009 0.014 0.51 -0.004 0.016 0.82 0.029 0.014 0.04 0.033 0.016 0.04 
GNA12 rs798489 C/T 0.018 0.015 0.22 0.011 0.017 0.50 0.034 0.015 0.02 0.029 0.017 0.08 
IGF2BP3 rs11765649 T/C 0.007 0.015 0.64 0.006 0.017 0.74 0.017 0.015 0.25 0.013 0.017 0.45 
TBX20 rs6959887 A/G 0.018 0.013 0.15 -0.002 0.014 0.89 0.040 0.013 1.7x10-3 0.036 0.014 0.01 
YKT6-GCK rs138715366 C/T -0.030 0.087 0.73 -0.147 0.097 0.13 0.186 0.087 0.03 0.230 0.098 0.02 
MLXIPL rs62466330 C/T 0.019 0.028 0.50 -0.015 0.031 0.62 0.104 0.028 2.2x10-4 0.129 0.031 3.3x10-5 
ANK1-NKX6-3 rs13266210 A/G 0.013 0.015 0.41 0.009 0.017 0.61 0.018 0.015 0.24 0.023 0.017 0.18 
TRIB1 rs6989280 G/A 0.014 0.014 0.32 0.019 0.016 0.24 -0.003 0.014 0.84 -0.012 0.016 0.46 
SLC45A4 rs12543725 G/A 0.012 0.013 0.36 0.004 0.015 0.79 0.013 0.013 0.31 0.014 0.015 0.34 
PTCH1 rs28510415 G/A 0.037 0.023 0.11 -0.005 0.026 0.84 0.105 0.023 8.0x10-6 0.105 0.027 7.2x10-5 
LPAR1 rs2150052 T/A 0.019 0.013 0.13 0.008 0.014 0.56 0.017 0.013 0.17 0.010 0.014 0.47 
PHF19 rs7847628 G/A 0.020 0.013 0.13 0.018 0.015 0.24 0.022 0.013 0.11 0.017 0.015 0.25 
STRBP rs700059 G/A 0.017 0.016 0.27 -0.006 0.018 0.76 0.053 0.016 8.0x10-4 0.062 0.018 4.5x10-4 





Index variant EA/ 
NEA 
  
Maternal effect on offspring birth weight Foetal effect on birth weight 
Unadjusted Adjusted for foetal genotype Unadjusted Adjusted for maternal genotype 
β SE P-value β SE P-value β SE P-value β SE P-value 
NT5C2 rs74233809 C/T -0.002 0.021 0.94 -0.010 0.024 0.67 0.016 0.021 0.44 0.011 0.024 0.64 
ADRB1 rs7076938 T/C 0.045 0.014 8.8x10-4 0.032 0.015 0.03 0.050 0.014 2.6x10-4 0.037 0.015 0.02 
PLEKHA1 rs2421016 T/C 0.017 0.012 0.17 0.018 0.014 0.19 0.006 0.012 0.63 0.001 0.014 0.95 
INS-IGF2 rs72851023 T/C 0.031 0.027 0.26 0.008 0.031 0.79 0.060 0.028 0.03 0.061 0.031 0.05 
MTNR1B rs10830963 G/C 0.047 0.015 1.7x10-3 0.035 0.017 0.04 0.049 0.015 9.8x10-4 0.032 0.017 0.06 
APOLD1 rs11055034 C/A -0.003 0.014 0.83 -0.013 0.016 0.42 0.005 0.014 0.72 0.011 0.016 0.51 
ABCC9 rs139975827 G/A 0.005 0.014 0.72 -0.011 0.015 0.47 0.033 0.014 0.02 0.041 0.015 0.01 
ITPR2 rs12823128 T/C -0.003 0.013 0.83 -0.016 0.015 0.28 0.022 0.013 0.10 0.024 0.015 0.10 
HMGA2 rs1351394 T/C 0.023 0.013 0.07 0.007 0.015 0.65 0.038 0.013 3.0x10-3 0.038 0.014 0.01 
IGF1 rs7964361 A/G -0.005 0.023 0.85 -0.016 0.026 0.55 0.025 0.023 0.28 0.030 0.026 0.25 
LINC00332 rs2324499 G/C 0.006 0.013 0.68 0.001 0.015 0.96 0.019 0.013 0.15 0.019 0.015 0.22 
RB1 rs2854355 G/A -0.013 0.015 0.37 -0.027 0.016 0.10 0.020 0.015 0.18 0.029 0.016 0.07 
RNF219-AS1 rs1819436 C/T 0.040 0.018 0.03 0.013 0.020 0.52 0.057 0.018 1.8x10-3 0.046 0.020 0.02 
FES rs12906125 G/A 0.006 0.014 0.66 -0.004 0.016 0.82 0.016 0.014 0.27 0.012 0.016 0.47 
IGF1R rs7402982 A/G 0.015 0.013 0.24 0.003 0.015 0.83 0.025 0.013 0.06 0.027 0.015 0.07 
GPR139 rs1011939 G/A 0.015 0.014 0.27 0.013 0.015 0.39 0.008 0.014 0.57 0.000 0.015 1.00 
CLDN7 rs113086489 T/C 0.018 0.013 0.16 0.002 0.014 0.89 0.043 0.013 5.7x10-4 0.044 0.014 1.9x10-3 
SUZ12P1-CRLF3 rs144843919 G/A 0.003 0.037 0.93 -0.030 0.041 0.47 0.045 0.038 0.24 0.047 0.043 0.27 
SP6-SP2 rs12942207 C/T -0.001 0.014 0.92 -0.003 0.016 0.82 0.007 0.014 0.63 0.008 0.015 0.59 
ACTL9 rs61154119 T/G -0.005 0.016 0.75 -0.022 0.018 0.23 0.032 0.016 0.05 0.041 0.018 0.02 
PEPD rs10402712 A/G -0.013 0.014 0.36 -0.028 0.016 0.07 0.016 0.014 0.26 0.025 0.016 0.11 
JAG1 rs6040076 C/G 0.000 0.013 0.98 -0.007 0.015 0.64 0.010 0.013 0.43 0.017 0.015 0.24 
C20orf203 rs28530618 A/G 0.015 0.013 0.23 0.013 0.014 0.34 0.006 0.013 0.63 0.003 0.014 0.85 
MAFB rs6016377 T/C 0.000 0.013 0.99 -0.021 0.015 0.16 0.042 0.013 1.4x10-3 0.058 0.015 9.9x10-5 
NRIP1 rs2229742 G/C 0.026 0.023 0.26 0.018 0.026 0.49 0.031 0.023 0.17 0.018 0.026 0.49 
KREMEN1 rs134594 C/T 0.016 0.013 0.22 0.007 0.015 0.64 0.017 0.013 0.20 0.015 0.015 0.30 
SREBF2 rs62240962 C/T 0.019 0.026 0.47 0.005 0.029 0.87 0.049 0.026 0.06 0.049 0.029 0.09 
PLAC1a rs11096402 G/A 0.009 0.022 0.68 -0.004 0.024 0.88 0.013 0.024 0.60 0.014 0.027 0.61 
aFor analysis of the PLAC1 locus on the X chromosome, we used female offsprings only: N = 4,940 mother-child pairs 
EA: Effect Allele. NEA: Non Effect Allele. SE: standard error. Effects (beta values) are aligned to the BW-raising allele as reported in Extended Data Table 1a. 
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Supplementary Table 12. Summary results of LD Score regression analyses between birth weight and various diseases, metabolic and 
anthropometric traits. 
 
(a) Birth weight and other traits 
Phenotype1 Phenotype2 Genetic 
Correlation (rg) 






Birth weight  Infant head circumference 0.389 0.073 5.30 1.2x10-7 10,770 1,019,674 22504419 
Birth weight  Birth length 0.805 0.058 13.98 2.0x10-44 28,460 983,823 25281659 
Birth weight  Height (2014) 0.406 0.027 15.18 4.8x10-52 253,300 1,049,262 25282103 
Birth weight  Height (2010) 0.401 0.028 14.09 4.6x10-45 133,900 1,026,905 20881960 
Birth weight  Height (women) 0.400 0.032 12.59 2.4x10-36 73,140 1,028,514 23754948 
Birth weight  Height (men) 0.384 0.035 11.00 3.7x10-28 60,590 1,024,139 23754948 
Birth weight  Extreme height 0.399 0.043 9.20 3.5x10-20 16,200 739,427 23563607 
Birth weight  Body mass index (2015) 0.114 0.025 4.49 7.3x10-6 322,200 1,050,986 25673413 
Birth weight  Body mass index (2010) 0.120 0.033 3.66 3.0x10-4 123,900 1,028,235 20935630 
Birth weight  Extreme Body mass index 0.116 0.048 2.40 0.017 16,070 738,850 23563607 
Birth weight  Body mass index (men) 0.148 0.040 3.67 2.4x10-4 58,670 1,025,063 23754948 
Birth weight  Body mass index (women) 0.096 0.035 2.76 0.006 67,960 1,029,327 23754948 
Birth weight  Weight (men) 0.377 0.039 9.57 1.1x10-21 58,350 1,025,155 23754948 
Birth weight  Weight (women) 0.280 0.036 7.70 1.4x10-14 67,590 1,029,320 23754948 
Birth weight  Waist-hip ratio (2015) -0.052 0.031 -1.66 0.097 212,200 1,048,211 25673412 
Birth weight  Waist-hip ratio (adjusted for BMI - 2015) -0.159 0.032 -4.93 8.3x10-7 210,100 1,051,567 25673412 
Birth weight  Waist-hip ratio (adjusted for BMI - 2010) -0.189 0.041 -4.59 4.4x10-6 77,220 1,027,370 20935629 
Birth weight  Waist-hip ratio (men) -0.080 0.053 -1.51 0.132 34,640 1,025,922 23754948 
Birth weight  Waist-hip ratio (women) -0.060 0.054 -1.11 0.268 42,730 1,029,620 23754948 
Birth weight  Extreme waist-hip ratio -0.254 0.071 -3.57 3.6x10-4 10,260 674,047 23563607 
Birth weight  Hip circumference 0.281 0.030 9.30 1.4x10-20 213,000 1,048,111 25673412 
Birth weight  Hip circumference (adjusted for BMI) 0.314 0.033 9.49 2.3x10-21 211,100 1,049,874 25673412 
Birth weight  Hip circumference (men) 0.339 0.063 5.34 9.3x10-8 32,850 1,030,276 23754948 
Birth weight  Hip circumference (women) 0.260 0.057 4.54 5.6x10-6 40,360 1,031,503 23754948 
Birth weight  Waist circumference 0.177 0.028 6.29 3.9x10-10 232,100 1,048,634 25673412 
Birth weight  Waist circumference (adjusted for BMI) 0.128 0.032 4.03 5.7x10-5 231,400 1,049,871 25673412 
Birth weight  Waist circumference (men) 0.218 0.053 4.11 3.9x10-5 38,310 1,025,680 23754948 
Birth weight  Waist circumference (women) 0.135 0.047 2.86 0.004 47,320 1,027,090 23754948 
Birth weight  Obesity (class 1) 0.102 0.035 2.97 0.003 98,700 965,717 23563607 
Birth weight  Obesity (class 2) 0.099 0.040 2.46 0.014 72,550 890,085 23563607 
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Phenotype1 Phenotype2 Genetic 
Correlation (rg) 






Birth weight  Obesity (class 3) 0.136 0.055 2.48 0.013 50,360 621,425 23563607 
Birth weight  Childhood obesity 0.192 0.049 3.95 7.8x10-5 13,850 1,057,303 22484627 
Birth weight  Overweight 0.061 0.033 1.83 0.067 158,900 1,012,975 23563607 
Birth weight  Anorexia nervosa 0.029 0.033 0.91 0.365 17,770 1,042,946 24514567 
Birth weight  Crohn's disease 0.047 0.044 1.07 0.284 20,883 1,066,772 26192919 
Birth weight  Irritable bowel syndrome 0.009 0.052 0.18 0.858 27,432 1,091,971 26192919 
Birth weight  Rheumatoid arthritis -0.004 0.046 -0.08 0.935 25,710 986,060 20453842 
Birth weight  Lumbar spine bone mineral density  -0.027 0.043 -0.63 0.531 31,800 1,061,087 22504420 
Birth weight  Lumbar spine bone mineral density (men) -0.098 0.064 -1.53 0.127 9,980 1,060,919 22504420 
Birth weight  Lumbar spine bone mineral density (women) -0.003 0.044 -0.07 0.943 22,180 1,064,756 22504420 
Birth weight  Femoral neck bone mineral density 0.013 0.039 0.34 0.736 32,960 1,065,335 22504420 
Birth weight  Femoral neck bone mineral density (men) -0.019 0.057 -0.33 0.745 9,971 1,056,535 22504420 
Birth weight  Femoral neck bone mineral density (women) 0.020 0.050 0.40 0.686 22,990 1,069,031 22504420 
Birth weight  Coronary artery disease -0.295 0.051 -5.80 6.5x10-9 84,270 932,642 21378990 
Birth weight  Systolic blood pressure (adjusted for BMI) -0.263 0.039 -6.72 1.8x10-11 69,395 990,423 21909115 
Birth weight Systolic blood pressure (unadjusted for BMI) -0.215 0.030 -7.21 5.5x10-13 127,969 1,186,583 
UK Biobank 
data 
Birth weight  Diastolic blood pressure (adjusted for BMI) -0.224 0.042 -5.35 8.7x10-8 69,395 990,446 21909115 
Birth weight  Triglycerides (2010) -0.167 0.038 -4.41 1.0x10-5 96,600 1,024,575 20686565 
Birth weight  Triglycerides (2013) -0.112 0.031 -3.61 3.0x10-4 177,900 1,026,718 24097068 
Birth weight  Total cholesterol (2010) -0.127 0.040 -3.21 0.001 100,200 1,026,024 20686565 
Birth weight  Total cholesterol (2013) -0.105 0.033 -3.17 0.002 187,400 1,027,605 24097068 
Birth weight  Low density lipoprotein (2010) -0.136 0.047 -2.90 0.004 95,450 1,024,730 20686565 
Birth weight  Low density lipoprotein (2013) -0.102 0.036 -2.87 0.004 173,100 1,026,705 24097068 
Birth weight  High density lipoprotein (2010) 0.087 0.039 2.23 0.026 99,900 1,026,029 20686565 
Birth weight  High density lipoprotein (2013) 0.056 0.029 1.97 0.048 187,200 1,027,731 24097068 
Birth weight  Type 2 diabetes -0.271 0.056 -4.88 1.1x10-6 69,030 976,437 22885922 
Birth weight  Fasting insulin -0.150 0.071 -2.10 0.036 46,190 1,054,692 20081858 
Birth weight  Fasting insulin (adjusting for BMI) -0.178 0.055 -3.26 0.001 51,750 1,121,151 22581228 
Birth weight  HbA1c -0.166 0.060 -2.75 0.006 46,368 1,109,233 20858683 
Birth weight  2hr glucose -0.245 0.094 -2.62 0.009 15,230 1,028,518 20081857 
Birth weight  Fasting glucose -0.073 0.054 -1.35 0.178 46,190 1,056,257 20081858 
Birth weight  Fasting glucose (adjusting for BMI) -0.126 0.048 -2.61 0.009 58,074 1,121,150 22581228 
Birth weight  HOMA-IR -0.133 0.072 -1.84 0.066 46,190 1,053,709 20081858 
Birth weight  HOMA-B -0.065 0.065 -1.00 0.317 46,190 1,053,581 20081858 
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Correlation (rg) 






Birth weight  Educational attainment (college) 0.111 0.042 2.63 0.009 126,600 1,017,448 25201988 
Birth weight  Educational attainment (years) 0.105 0.043 2.43 0.015 126,600 1,014,207 25201988 
Birth weight  Childhood intelligence 0.123 0.075 1.64 0.100 17,990 800,741 25201988 
Birth weight  Autism -0.089 0.053 -1.69 0.091 10,263 944,654 23453885 
Birth weight  ADHD -0.107 0.103 -1.04 0.300 3,351 1,065,753 20732625 
Birth weight  Major depressive disorder -0.076 0.074 -1.02 0.306 18,760 887,434 22472876 
Birth weight  Bipolar disorder 0.026 0.047 0.56 0.578 16,730 800,584 21926972 
Birth weight  Alzheimer's disease -0.039 0.080 -0.49 0.622 74,050 1,142,332 24162737 
Birth weight  Schizophrenia -0.022 0.044 -0.49 0.624 21,860 846,564 21926974 
Birth weight  
Pubertal growth - height at age 10 in females 
and 12 in males - targets take-off phase of 
growth spurt 0.271 0.051 5.28 1.3x10-7 13,960 1,009,067 23449627 
Birth weight  Pubertal growth - height at age 12 in males 0.305 0.072 4.23 2.3x10-5 6,986 1,017,307 23449627 
Birth weight  Pubertal growth - height at age 10 in females 0.221 0.061 3.63 3.0x10-4 6,974 1,036,441 23449627 
Birth weight  
Pubertal growth - total amount of growth 
across the pubertal growth period 0.162 0.062 2.61 0.009 10,800 1,037,500 23449627 
Birth weight  
Pubertal growth - total amount of growth 
across the pubertal growth period (males) 0.173 0.080 2.15 0.032 5,043 1,039,045 23449627 
Birth weight  
Pubertal growth - total amount of growth 
across the pubertal growth period (females) 0.142 0.083 1.70 0.089 5,756 1,038,734 23449627 
Birth weight  
Pubertal growth - total amount of growth in 
late adolescence, targeting the timing of peak 
height growth velocity 0.109 0.075 1.46 0.145 4,282 1,039,103 23449627 
Birth weight  
Pubertal growth - total amount of growth in 
late adolescence (males) 0.041 0.081 0.51 0.613 4,282 1,039,103 23449627 
Birth weight  
Pubertal growth - total amount of growth in 
late adolescence (females) 0.230 0.112 2.06 0.039 4,946 1,038,829 23449627 
Birth weight  Age at menarche (2014) 0.029 0.031 0.93 0.354 133,000 1,057,631 25231870 
Birth weight  Pubertal growth - Tanner scale -0.137 0.125 -1.10 0.273 9,918 969,224 23449627 
Birth weight  Pubertal growth - Tanner scale (males) -0.453 0.650 -0.97 0.486 3,769 969,224 23449627 
Birth weight  Pubertal growth - Tanner scale (females) -0.037 0.138 -0.27 0.786 6,149 969,224 23449627 
Birth weight  Asthma 0.050 0.069 0.72 0.471 10,770 1,019,674 20860503 
Birth weight  Ever smoked 0.007 0.045 0.15 0.878 28,460 983,823 20418890 
Birth weight  Former smoker 0.097 0.061 1.58 0.114 253,300 1,049,262 20418890 
Birth weight  Cigarettes per day -0.042 0.064 -0.67 0.505 133,900 1,026,905 20418890 
Birth weight  Smoking start age 0.041 0.087 0.47 0.636 73,140 1,028,514 20418890 
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(b) Glucose-Related Phenotypes 
Phenotype1 Phenotype2 Genetic 
Correlation (rg) 






Type 2 diabetes Fasting glucose 0.587 0.097 6.07 1.3x10-9 46,190 1,056,257 20081858 
Type 2 diabetes 2hr glucose 0.301 0.12 2.47 0.014 15,230 1,028,518 20081857 
Type 2 diabetes Fasting insulin 0.435 0.12 3.56 4.0x10-4 46,190 1,054,692 20081858 
Type 2 diabetes HOMA-B -0.002 0.11 -0.01 0.989 46,190 1,053,581 20081858 
SE, standard error; BMI, body mass index; ADHD, attention deficit hyperactive disorder; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-B, 
homeostasis model assessment of beta cell function. 
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Supplementary Table 13. Estimating the proportion of the BW-adult phenotype covariance attributable to genotyped SNPs in UK Biobank 
and the Northern Finland Birth Cohort (NFBC) 1966 data. 
 
 




















Proportion of covariance 
explained by genetic 
variants directly genotyped: 
gcov/(gcov+rcov)b (95% CI) 
UK Biobank 








(0.008) 0.96 (0.36, 1.56) 
Systolic blood pressure (unadjusted for 








(0.008) 0.85 (0.70, 0.99) 








(0.007) 0.62 (0.54, 0.71) 








(0.007) 0.54 (0.44, 0.64) 

















(0.007) 0.54 (0.50, 0.58) 








(0.018) 0.55 (0.45, 0.64) 








(0.012) 0.65 (0.58, 0.71) 








(0.018) 0.38 (0.24, 0.53) 








(0.013) 0.58 (0.45, 0.72) 








(0.008) 0.39 (0.17, 0.61) 








(0.013) 0.49 (-0.01, 0.98) 








(0.018) 0.35 (-0.06, 0.77) 








(0.013) 0.44 (0.17, 0.71) 
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Proportion of covariance 
explained by genetic 
variants directly genotyped: 
gcov/(gcov+rcov)b (95% CI) 
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(0.013) 0.80 (-1.07, 2.68) 








(0.008) 0.19 (0.10, 0.28) 








(0.008) 0.83 (0.60, 1.05) 








(0.018) 0.35 (0.01, 0.68) 








(0.013) 0.63 (0.25, 1.01) 








(0.008) 0.61 (0.48, 0.73) 








(0.008) 0.85 (0.75, 0.96) 








(0.018) 0.51 (0.30, 0.73) 








(0.013) 0.66 (0.43, 0.89) 








(0.013) 0.49 (-0.72, 1.71) 








(0.008) 0.25 (-0.67, 1.16) 
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Proportion of covariance 
explained by genetic 
variants directly genotyped: 
gcov/(gcov+rcov)b (95% CI) 


























































































(0.043) 0.35 (-0.07, 1.28) 
aThe number of case/control was T2D: 1,488/55,166, CAD: 1,959/55,756, obesity1: 19,820/13,802, obesity2: 4,026/13,802, obesity3: 1,146/13,802, overweight: 
37,631/19,820, asthma: 7,131/50,584, ever smoker: 24,774/32,186, and former smoker: 18,721/32,186  The covariance for these traits were on the observed scale. 
bWe have put N/A (not applicable) when the genetic and residual covariances are in the opposite direction and it is not relevant to calculate gcov/(gcov + rcov). Although 
genetic covariance is subject to high uncertainty, there is a general pattern across both UK Biobank and the NFBC1966 that the phenotypic covariation between low BW 




Supplementary Table 14. List of 77 reported imprinted regions used in the current analysis.  
 
Gene Type Entrez ID Chr Gene Start site 
(bp, b37) 
Gene End site 
(bp, b37) 
CPA4 GTEX Primary 51200 7  129,932,973   129,964,020  
CST1 GTEX Primary 1469 20  23,728,189   23,731,574  
DIRAS3 GTEX Primary 9077 1  68,511,644   68,516,460  
DLK1 GTEX Primary 8788 14  101,193,201   101,201,467  
FAM50B GTEX Primary 26240 6  3,849,631   3,851,551  
GRB10 GTEX Primary 2887 7  50,657,759   50,861,159  
H19 GTEX Primary 283120 11  2,016,405   2,019,065  
IGF2 GTEX Primary 3481 11  2,150,346   2,170,833  
IGF2AS GTEX Primary 51214 11  2,161,757   2,169,896  
INPP5F GTEX Primary 22876 10  121,485,608   121,588,659  
KCNQ1 GTEX Primary 3784 11  2,466,220   2,870,340  
KIF25 GTEX Primary 3834 6  168,418,552   168,445,769  
L3MBTL1 GTEX Primary 26013 20  42,136,319   42,170,534  
LPAR6 GTEX Primary 10161 13  48,985,181   49,018,840  
MAGEL2 GTEX Primary 54551 15  23,888,695   23,892,993  
MAGI2 GTEX Primary 9863 7  77,646,373   79,082,890  
MEG3 GTEX Primary 55384 14  101,292,444   101,327,360  
MEG8 GTEX Primary 79104 14  101,361,106   101,373,305  
MEST GTEX Primary 4232 7  130,126,045   130,146,131  
NAP1L5 GTEX Primary 266812 4  89,617,065   89,619,023  
NDN GTEX Primary 4692 15  23,930,553   23,932,450  
NTM GTEX Primary 50863 11  131,240,370   132,206,716  
PEG10 GTEX Primary 23089 7  94,285,636   94,299,006  
PEG3 GTEX Primary 5178 19  57,321,444   57,352,094  
PLAGL1 GTEX Primary 5325 6  144,261,436   144,385,735  
PPIEL GTEX Primary 728448 1  39,987,951   40,025,370  
PPP2R5D GTEX Primary 5528 6  42,952,329   42,980,080  
PWRN1 GTEX Primary 791114 15  24,803,303   24,832,926  
SGK2 GTEX Primary 10110 20  42,187,634   42,214,273  
SNRPN GTEX Primary 6638 15  25,068,793   25,223,729  
SNURF GTEX Primary 8926 15  25,200,069   25,223,729  
SYCE1 GTEX Primary 93426 10  135,367,403   135,382,876  
UBE3A GTEX Primary 7337 15  25,582,395   25,684,128  
UGT2B4 GTEX Primary 7363 4  70,345,882   70,361,626  
UTS2 GTEX Primary 10911 1  7,907,671   7,913,551  
ZDBF2 GTEX Primary 57683 2  207,139,522   207,179,148  
ZNF331 GTEX Primary 55422 19  54,024,176   54,083,523  
ZNF597 GTEX Primary 146434 16  3,486,109   3,493,490  
ABCA6 GTEX suggestive (S4 unique) 23460 17  67,074,846   67,138,015  
BMP8A GTEX suggestive (S4 unique) 353500 1  39,957,317   39,995,541  
CHIT1 GTEX suggestive (S4 unique) 1118 1  203,185,206   203,198,860  
DLGAP2 GTEX suggestive (S4 unique) 9228 8  1,449,568   1,656,642  
DZIP1 GTEX suggestive (S4 unique) 22873 13  96,230,455   96,296,957  
EMR1 GTEX suggestive (S4 unique) 2015 19  6,887,581   6,940,464  
FKBP10 GTEX suggestive (S4 unique) 60681 17  39,968,961   39,979,469  
GPR1 GTEX suggestive (S4 unique) 2825 2  207,040,041   207,082,771  
GTSF1 GTEX suggestive (S4 unique) 121355 12  54,849,735   54,867,386  
GUCY1B2 GTEX suggestive (S4 unique) 2974 13  51,568,646   51,640,293  
KIR3DX1 GTEX suggestive (S4 unique) 90011 19  55,043,908   55,055,195  
LRRTM1 GTEX suggestive (S4 unique) 347730 2  80,529,002   80,531,487  
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Gene Type Entrez ID Chr Gene Start site 
(bp, b37) 
Gene End site 
(bp, b37) 
MYOM2 GTEX suggestive (S4 unique) 9172 8  1,993,157   2,093,380  
RTL1 GTEX suggestive (S4 unique) 388015 14  101,346,991   101,351,184  
SERPINA6 GTEX suggestive (S4 unique) 866 14  94,770,584   94,789,688  
SLC10A2 GTEX suggestive (S4 unique) 6555 13  103,696,347   103,719,196  
THNSL2 GTEX suggestive (S4 unique) 55258 2  88,469,834   88,486,146  
ANO1 GTEX consistent (S6) 55107 11  69,924,407   70,035,652  
CALCR GTEX consistent (S6) 799 7  93,053,798   93,204,042  
CDKN1C GTEX consistent (S6) 1028 11  2,904,447   2,906,995  
COPG2 GTEX consistent (S6) 26958 7  130,146,079   130,353,598  
DCN GTEX consistent (S6) 1634 12  91,539,034   91,576,806  
DIO3 GTEX consistent (S6) 1735 14  102,027,687   102,029,789  
DLX5 GTEX consistent (S6) 1749 7  96,649,701   96,654,143  
GABRA5 GTEX consistent (S6) 2558 15  27,111,865   27,194,357  
GABRG3 GTEX consistent (S6) 2567 15  27,216,428   27,778,373  
GLIS3 GTEX consistent (S6) 169792 9  3,824,127   4,300,035  
GNAS-AS1 GTEX consistent (S6) 149775 20  57,393,972   57,425,958  
KLF14 GTEX consistent (S6) 136259 7  130,417,395   130,418,888  
MKRN3 GTEX consistent (S6) 7681 15  23,810,453   23,813,166  
NNAT GTEX consistent (S6) 4826 20  36,149,606   36,152,090  
C15orf2 GTEX consistent (S6) 23742 15  24,920,540   24,928,593  
PON3 GTEX consistent (S6) 5446 7  94,989,183   95,025,687  
RB1 GTEX consistent (S6) 5925 13  48,877,882   49,056,026  
RBP5 GTEX consistent (S6) 83758 12  7,276,279   7,281,466  
SGCE GTEX consistent (S6) 8910 7  94,214,535   94,285,521  
TH GTEX consistent (S6) 7054 11  2,185,158   2,193,035  
TSPAN32 GTEX consistent (S6) 10077 11  2,323,242   2,339,430  
TSSC4 GTEX consistent (S6) 10078 11  2,423,522   2,425,106  
These 77 regions were highlighted in reference 10: Baran Y et al. Genome Res 25, 927-936 (2015). 
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Supplementary Table 15. Comparison of variance in BW between individuals heterozygous and 
homozygous for each of the 59 autosomal BW index SNPs (plus DLK1) in 57,715 UK Biobank 
samples. 
 
Locus Index variant Alleles 
A/B 
Variance Effect 
AA AB BB β SE P-value 
WNT4-ZBTB40  rs2473248 T/C 1.008 0.971 1.007 -0.015 0.006 0.99 
ZBTB7B  rs3753639 T/C 0.994 1.004 1.026 0.002 0.005 0.34 
FCGR2B  rs72480273 A/C 0.995 1.008 1.012 0.008 0.005 6.4x10-2 
DTL rs61830764 G/A 0.997 0.993 1.031 -0.004 0.005 0.81 
ATAD2B  rs7575873 A/G 1.007 0.978 0.964 -0.014 0.006 0.99 
EPAS1  rs1374204 C/T 0.968 0.999 1.005 -0.002 0.005 0.68 
PTH1R  rs2242116 A/G 1.003 0.987 1.013 -0.010 0.005 0.98 
ADCY5  rs11719201 C/T 0.984 1.019 1.023 0.016 0.005 1.1x10-3 
CPA3  rs10935733 T/C 0.999 1.007 0.990 0.009 0.005 3.7x10-2 
CCNL1-LEKR1  rs13322435 A/G 1.016 0.993 0.981 -0.007 0.005 0.91 
LCORL  rs925098 G/A 1.011 0.996 1.001 -0.002 0.005 0.64 
HHIP  rs6537307 A/G 0.972 1.004 1.019 0.005 0.005 0.18 
5q11.2  rs854037 A/G 1.004 0.990 1.008 -0.009 0.005 0.95 
EBF1  rs7729301 G/A 1.028 0.990 1.003 -0.007 0.005 0.93 
CDKAL1  rs35261542 C/A 1.004 0.998 0.969 2x10-4 0.005 0.48 
HIST1H2BE rs9379832 A/G 1.004 0.995 0.995 -0.004 0.005 0.80 
HMGA1  rs7742369 A/G 0.995 1.005 1.044 0.002 0.005 0.36 
L3MBTL3  rs1415701 G/A 1.006 0.990 1.006 -0.009 0.005 0.96 
ESR1  rs1101081 C/T 1.003 0.999 0.979 0.001 0.005 0.39 
GNA12  rs798489 C/T 1.005 0.993 0.997 -0.005 0.005 0.81 
IGF2BP3  rs11765649 T/C 1.004 0.991 1.007 -0.005 0.005 0.83 
TBX20  rs6959887 A/G 0.998 1.001 0.999 0.004 0.005 0.21 
YKT6-GCK rs138715366 C/T 1.001 0.888 0.657 -0.070 0.019 1.00 
MLXIPL rs62466330 T/C 0.995 1.028 1.036 0.016 0.007 1.3x10-2 
ANK1-NKX6-3  rs13266210 A/G 1.007 0.984 1.009 -0.013 0.005 0.99 
TRIB1 rs6989280 G/A 0.997 1.005 0.992 0.005 0.005 0.18 
SLC45A4  rs12543725 G/A 1.009 0.994 0.999 -0.009 0.005 0.97 
PTCH1  rs28510415 A/G 0.999 0.999 1.017 1x10-4 0.007 0.49 
LPAR1  rs2150052 A/T 0.980 1.002 1.015 0.002 0.005 0.37 
PHF19  rs7847628 A/G 0.984 1.002 1.001 0.003 0.005 0.30 
STRBP  rs700059 G/A 0.989 1.018 0.994 0.015 0.006 4.4x10-3 
HHEX-IDE  rs61862780 T/C 1.005 0.996 1.003 -0.005 0.005 0.82 
NT5C2 rs74233809 T/C 0.999 0.998 1.136 3x10-4 0.007 0.48 
ADRB1  rs7076938 C/T 0.992 1.003 0.998 6x10-4 0.005 0.45 
PLEKHA1  rs2421016 C/T 0.988 1.007 0.998 0.008 0.005 6.1x10-2 
INS-IGF2  rs72851023 C/T 0.996 1.022 1.013 0.013 0.007 3.4x10-2 
MTNR1B  rs10830963 C/G 0.994 1.008 0.997 0.005 0.005 0.18 
APOLD1 rs11055034 C/A 1.002 1.000 0.985 2x10-4 0.005 0.49 
ABCC9  rs139975827 G/A 1.006 1.000 0.982 2x10-4 0.005 0.48 
ITPR2 rs12823128 T/C 1.014 0.993 0.998 -0.006 0.005 0.87 
HMGA2  rs1351394 T/C 1.003 1.001 0.993 9x10-4 0.005 0.43 
IGF1  rs7964361 G/A 0.999 1.006 0.991 0.003 0.007 0.35 
LINC00332 rs2324499 G/C 1.000 0.998 1.004 -0.003 0.005 0.70 
RB1 rs2854355 A/G 0.991 1.008 1.024 0.008 0.005 5.4x10-2 
RNF219-AS1  rs1819436 T/C 1.034 1.003 0.998 5x10-4 0.006 0.47 
DLK1 rs6575803 C/T 1.002 0.991 0.987 -0.007 0.006 0.87 
FES  rs12906125 G/A 1.004 0.993 1.010 -0.005 0.005 0.86 
IGF1R  rs7402982 A/G 0.994 0.998 1.006 -0.003 0.005 0.73 
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Locus Index variant Alleles 
A/B 
Variance Effect 
AA AB BB β SE P-value 
GPR139 rs1011939 G/A 1.022 1.006 0.991 0.005 0.005 0.14 
CLDN7  rs113086489 C/T 0.991 1.002 1.002 0.001 0.005 0.41 
SUZ12P1-CRLF3  rs144843919 G/A 1.000 0.990 0.955 -0.006 0.010 0.72 
SP6-SP2 rs12942207 C/T 1.018 1.005 0.992 0.006 0.005 0.12 
ACTL9 rs61154119 T/G 0.998 1.007 0.974 0.003 0.006 0.30 
PEPD rs10402712 G/A 1.005 0.993 0.998 -0.004 0.005 0.78 
JAG1  rs6040076 G/C 0.989 1.003 1.003 0.004 0.005 0.22 
C20orf203  rs28530618 A/G 1.002 1.000 0.997 4x10-4 0.005 0.47 
MAFB rs6016377 C/T 0.988 0.999 1.021 2x10-4 0.005 0.48 
NRIP1 rs2229742 G/C 1.002 0.991 0.939 -0.006 0.006 0.83 
KREMEN1  rs134594 C/T 1.020 1.009 0.983 0.005 0.005 0.14 
SREBF2  rs62240962 C/T 1.003 0.985 0.983 -0.008 0.007 0.89 
The beta value is a parameter of the Brown-Forsythe test that measures how different the mean absolute deviations 
(MADs) are from the respective group medians in the heterozygous vs the homozygous group. SE, standard error.
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Supplementary Table 16. Parent-of-origin specific analysis at 59 autosomal BW loci (plus DLK1) 
in 4,908 ALSPAC mother-child pairs. 
 
Locus  SNP EA/
NEA 
Paternal transmission Maternal transmission P_het 
β SE P-value β SE P-value 
WNT4-
ZBTB40  rs2473248 C/T 0.019 0.042 0.65 0.189 0.076 1.3x10-2 6.1x10-2 
ZBTB7B  rs3753639 C/T 0.012 0.034 0.72 0.078 0.045 8.5x10-2 0.34 
FCGR2B  rs72480273 C/A 0.097 0.037 8.0x10-3 0.060 0.047 0.20 0.17 
DTL rs61830764 A/G 0.067 0.031 2.8x10-2 0.096 0.030 1.7x10-3 0.44 
ATAD2B  rs7575873 A/G 0.080 0.041 5.3x10-2 0.086 0.072 0.23 0.36 
EPAS1  rs1374204 T/C 0.094 0.032 3.7x10-3 0.121 0.037 1.1x10-3 0.98 
PTH1R  rs2242116 A/G 0.007 0.031 0.83 0.064 0.033 5.2x10-2 9.8x10-2 
ADCY5  rs11719201 T/C 0.137 0.034 4.5x10-3 0.062 0.035 7.5x10-2 0.11 
CPA3  rs10935733 T/C 0.052 0.029 7.7x10-2 0.013 0.031 0.67 0.19 
CCNL1-LEKR1  rs13322435 A/G 0.117 0.031 1.4x10-4 0.088 0.032 5.9x10-3 0.48 
LCORL  rs925098 G/A 0.128 0.033 1.1x10-4 0.063 0.042 0.13 0.18 
HHIP  rs6537307 G/A 0.080 0.030 8.1x10-3 0.071 0.030 1.9x10-2 0.79 
5q11.2  rs854037 A/G 0.078 0.037 3.5x10-2 0.081 0.043 5.8x10-2 0.90 
EBF1  rs7729301 A/G -0.006 0.034 0.86 -0.028 0.041 0.50 0.67 
CDKAL1  rs35261542 C/A 0.101 0.033 2.1x10-3 0.040 0.041 0.32 8.3x10-2 
HIST1H2BE rs9379832 A/G 0.034 0.033 0.30 0.037 0.038 0.33 0.83 
HMGA1  rs7742369 G/A 0.046 0.038 0.23 0.161 0.051 1.6x10-3 0.10 
L3MBTL3  rs1415701 G/A 0.029 0.033 0.38 0.092 0.042 2.8x10-2 9.2x10-2 
ESR1  rs1101081 C/T 0.074 0.033 2.5x10-2 0.025 0.039 0.53 0.16 
GNA12  rs798489 C/T 0.011 0.033 0.74 0.043 0.040 0.29 0.35 
IGF2BP3  rs11765649 T/C -0.013 0.033 0.69 0.054 0.036 0.14 0.14 
TBX20  rs6959887 A/G 0.035 0.032 0.27 0.035 0.033 0.29 0.94 
YKT6-GCK rs138715366 C/T 0.235 0.166 0.16 0.032 0.468 0.95 0.66 
MLXIPL rs62466330 C/T 0.107 0.053 4.5x10-2 0.166 0.094 7.8x10-2 0.87 
ANK1-NKX6-3  rs13266210 A/G 0.039 0.036 0.28 -0.031 0.041 0.45 0.21 
TRIB1 rs6989280 G/A -0.012 0.034 0.73 0.018 0.040 0.66 0.60 
SLC45A4  rs12543725 G/A 0.052 0.030 8.6x10-2 0.047 0.030 0.12 0.90 
PTCH1  rs28510415 G/A 0.091 0.047 5.4x10-2 0.212 0.092 2.1x10-2 0.39 
LPAR1  rs2150052 T/A -0.001 0.030 0.97 0.092 0.030 2.0x10-3 2.4x10-3 
PHF19  rs7847628 G/A 0.038 0.032 0.23 0.004 0.037 0.92 0.28 
STRBP  rs700059 G/A 0.043 0.041 0.29 -0.029 0.070 0.68 0.22 
HHEX-IDE  rs61862780 T/C 0.085 0.030 4.7x10-3 0.050 0.030 9.6x10-2 0.32 
NT5C2 rs74233809 C/T -0.018 0.051 0.73 0.040 0.068 0.56 0.51 
ADRB1  rs7076938 T/C 0.023 0.033 0.49 0.078 0.041 5.5x10-2 0.27 
PLEKHA1  rs2421016 T/C 0.024 0.031 0.43 0.036 0.031 0.24 0.77 
INS-IGF2  rs72851023 T/C 0.116 0.051 2.2x10-2 0.108 0.107 0.31 0.56 
MTNR1B  rs10830963 G/C 0.024 0.033 0.46 0.058 0.040 0.15 0.53 
APOLD1 rs11055034 C/A 0.122 0.032 1.7x10-4 0.053 0.039 0.17 3.2x10-2 
ABCC9  rs139975827 G/A 0.045 0.031 0.15 0.017 0.032 0.59 0.46 
ITPR2 rs12823128 T/C 0.064 0.030 3.0x10-2 -0.003 0.029 0.91 7.7x10-2 
HMGA2  rs1351394 T/C 0.015 0.031 0.63 0.082 0.031 8.3x10-3 8.0x10-2 
IGF1  rs7964361 A/G -0.045 0.049 0.36 0.091 0.099 0.36 0.33 
LINC00332 rs2324499 G/C 0.012 0.032 0.70 0.041 0.034 0.22 0.70 
RB1 rs2854355 G/A 0.031 0.033 0.35 -0.012 0.042 0.77 0.25 
RNF219-AS1  rs1819436 C/T 0.038 0.042 0.36 0.136 0.079 8.4x10-2 0.39 
DLK1 rs6575803 C/T 0.104 0.045 2.2x10-2 0.205 0.091 2.5x10-2 0.40 
FES  rs12906125 G/A 0.019 0.032 0.55 0.095 0.035 6.7x10-3 9.3x10-2 








Paternal transmission  Maternal transmission P_het 
  β SE P-value β SE P-value 
GPR139 rs1011939 G/A -0.028 0.032 0.38 0.021 0.038 0.59 0.29 
CLDN7  rs113086489 T/C 0.061 0.031 4.9x10-2 0.050 0.031 0.11 0.83 
SUZ12P1-
CRLF3  rs144843919 G/A 0.003 0.071 0.96 0.182 0.113 0.11 0.20 
SP6-SP2 rs12942207 C/T 0.050 0.032 0.12 0.027 0.038 0.48 0.32 
ACTL9 rs61154119 T/G 0.056 0.038 0.14 0.164 0.062 8.7x10-3 5.6x10-2 
PEPD rs10402712 A/G 0.077 0.033 2.1x10-2 0.001 0.034 0.98 0.10 
JAG1  rs6040076 C/G 0.028 0.031 0.36 0.001 0.031 0.97 0.53 
C20orf203  rs28530618 A/G 0.053 0.031 8.3x10-2 0.013 0.031 0.68 0.26 
MAFB rs6016377 T/C 0.054 0.031 8.0x10-2 0.008 0.031 0.80 0.20 
NRIP1 rs2229742 G/C 0.020 0.046 0.66 0.030 0.095 0.75 0.89 
KREMEN1  rs134594 C/T 0.024 0.031 0.43 0.052 0.035 0.13 0.75 
SREBF2  rs62240962 C/T -0.004 0.052 0.94 0.088 0.065 0.18 0.40 
EA, effect allele; NEA, non effect allele; SE, standard error; P_het, P-value for difference in BW between AB 
heterozygote offspring inheriting allele A from mother and B from father, and those inheriting A from father and B 
from mother. 
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Supplementary Table 17. Association of BW signals with various adult metabolic and 
anthropometric traits. (GWAS look-ups) 
 
Provided in a separate Excel file. 
 
 
Supplementary Table 18. Effect of transmitted and untransmitted maternal haplotype scores on 




Height Systolic blood pressure Type 2 diabetes 
β SE P-value β SE P-value β SE P-value 
M1 (C1) 0.128 0.013 1.6x10-21 -6.82 3.36 0.04 -0.44 1.73 0.80 
M2 0.010 0.012 0.39 -6.40 2.63 0.02 1.66 1.42 0.24 
C2 0.066 0.012 1.2x10-7 0.14 2.62 0.96 -2.94 1.47 0.045 
Beta values are in grams per weighted trait-raising allele. SE, standard error. 
M1(C1), maternal transmitted haplotype score; M2, Maternal untransmitted haplotype score; C2, paternal 




Supplementary Table 19. Reciprocal approximate conditional analyses at YKT6-GCK variants associated with birth weight (BW) or fasting 








BW SNP conditioned on FG SNP FG SNP conditioned on BW SNP 
Uncondit
ioned P  
Conditioned 
on Variant type 
Conditio











BW lead SNP 
(at YKT6 
intron 1)  
  
T/C 0.0089  
7.2x10-26 unconditioned - - - - - - 
 
rs878521 
GCK FG primary 
(ENGAGE1) 1.3x10-25 rs878521 rs138715366 0.12 0.28 
 
rs10259649 
GCK FG secondary 
(ENGAGE1) 7.7x10-26 rs10259649 rs138715366 0.52 0.63 
 rs4607517 GCK FG (MAGIC2) 2.6x10-25 rs4607517 rs138715366 3.2x10-4 1.2x10-3 











8.9x10-24 unconditioned - - - - - - 
 
rs878521 
GCK FG primary 
(ENGAGE1) 1.6x10-23 rs878521 rs78412508 0.12 0.27 
 
rs10259649 
GCK FG secondary 
(ENGAGE1) 9.7x10-24 rs10259649 rs78412508 0.52 0.66 
 rs4607517 GCK FG (MAGIC2) 3.1x10-23 rs4607517 rs78412508 3.2x10-4 1.2x10-3 
 rs10278336 GCK T2D (DIAGRAM3) 2.2x10-23 rs10278336 rs78412508 0.057 0.18 
EA, effect allele; NEA, non effect allele, EAF, effect allele frequency; Eur, European; BW, birth weight; FG, fasting glucose; T2D, type 2 diabetes. 
1. Horikoshi M et al. PLoS Genet 11, e1005230 (2015). 
2. Dupuis J et al. Nat Genet 42, 105-116 (2010). 
3. Morris AP et al. Nat Genet 44, 981-990 (2012). 
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Supplementary Figure 1. BW association enrichment for DNaseI hypersensitive (DHS) sites in 128 
cell types and four genic annotations. a, Each cell type DHS annotation and four gene-based 
annotations were individually tested for enrichment using the Bayes Factors for all variants in the 
62 credible sets. The effect estimate (filled circle) and 95% CI (horizontal line) are plotted on the x 
axis. The 128 cell types (listed on the y axis; see Supplementary Table 8 for details) are categorised 
according to the description fields from ENCODE (stem cell, neonatal, foetal, embryonic and adult 
groups). We considered an annotation enriched if the 95% CI did not overlap zero (highlighted in 
red). b, Estimated effect of enrichment (filled circle) and 95% CI (horizontal line) for each 
categorical field, tested in a joint model, are plotted (see Methods).   
 











ln(Enrichment) +/- 95% CI







ln(Enrichment) +/- 95% CI
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Supplementary Figure 2. Estimates of phenotypic, genetic and residual correlations (a) and 
estimates of genetic and residual covariance (b) between birth weight and adult metabolic or 
anthropometric traits in UK Biobank ‘white British’ samples (up to N=57,715). See details in 
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